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ABSTRACT 
Background & Objectives:  
Magnesium deficiency has been proposed as a novel factor implicated in the pathogenesis 
of diabetic complications. Hypomagnesemia can be both a consequence and a cause of diabetic 
complications. The aim of our study was to know the relationship between magnesium levels and 
diabetes and also note its association with the level of control of diabetes.  
Methods:  
This study was undertaken in PSG institute of medical research and hospital  Research in 
coimbatore from May 2014 to September 2014. A total of 50 cases of type-2 diabetes mellitus 
were taken for the study after satisfying the inclusion and exclusion criteria. 50 non diabetic 
patients were taken as controls. All the patients were evaluated in detail and serum magnesium 
levels were estimated using calmagite method.  
Results:  
The serum magnesium levels among cases and controls were 1.47 ± 0.20 mg/dl and 1.67 
± 0.20 mg/dl respectively. The serum magnesium levels in controlled and uncontrolled were 1.57 
± 0.20 mg/dl and 1.41 ± 0.20 mg/dl respectively.  
Interpretation and Conclusion: 
There was significant reduction in serum magnesium levels in diabetics compared to the 
controls. There was a significant correlation between magnesium levels and the level of control 
of diabetes. The levels of magnesium were found to be lower in uncontrolled diabetics. 
 
 
  
INTRODUCTION 
 
Diabetes mellitus is a common metabolic disorder that is characterised by hyperglycemia. 
Diabetes mellitus etiology is based on  factors which leads to persistent   hyperglycemia  are  
decreased  insulin production from beta cells , tissue utilizing glucose getting decreased  and 
increase in synthesis of glucose . This persisting hyperglycemia can cause multiorgan 
dysfunction like retina, kidney, peripheral nerve, heart and atherosclerotic changes. 
The most of cases of diabetes mellitus were broadly classified in to two categories. 
Insulin dependent diabetes mellitus (IDDM) and non insulin dependent diabetes mellitus 
(NIDDM). Both these types of  diabetes mellitus  are usually proceeded by a phase where there 
is a impairment in maintenance of blood glucose level is considered as a  progression in  
pathogenic process. Type 1 diabetes mellitus usually occurs due to  insulin deficiency which can 
either be complete or partial deficiency. Whereas type 2  diabetes mellitus is due to both due to 
sensitization of tissue to  insulin action is decreased and inability of beta cells to compensate 
there by resulting in inadequate insulin secretion. Several pathological features are seen in 
persons developing diabetes mellitus and long term complications.  Persons who have type 1 
diabetes mellitus , always have a  immunological trigger which is mediated through genetic 
factors  which  initiates an autoimmune response, which decreases gradually  the beta cell mass. 
This decline in beta cell mass usually varies depending on individuals as it  may not be similar in 
every one. This progressive and prolonged  impairment in insulin secretion causes diabetes 
where around 80% of beta cell mass would be destroyed. In type 2 diabetes mellitus, the 
individual becomes more resistant to insulin thereby insulin level increases .  Thereby failure to 
  
compensate insulin secretion results initially in impaired glucose tolerance  and utimately in type 
2 diabetes mellitus. 
Most common  acute complications in type 1 diabetes mellitus is  diabetic ketoacidosis  
and hyperglycemic hyperosmolar state which is more common in type 2 . Chronic complications 
of diabetes mellitus include microvascular complications and macrovascular complications. The 
microvascular complications are diabetic retinopathy, macular edema, diabetic neuropathy and 
diabetes related renal involvement. The macrovascular complications include cardiovascular 
disease like coronary artery disease and neurological disease like  cerebrovascular accident other 
macrovasular complications include are peripheral vascular disease. Because of insufficient  
action of insulin on target tissues carbohydrate metabolism is mostly affected. Fat  and protein 
are also affected in diabetes . Several vitamins and minerals act as a cofactor in the enzyme 
reaction regulated by insulin . These vitamins and minerals deficiencies such as vitamin E, 
potassium, zinc , chromium and magnesium can  aggravate carbohydrate intolerance. Among 
these persons either potassium or magnesium replacement can be detected easily based on low 
serum levels.  
Magnesium is widely distributed and it’s concentration can be particularly seen in the 
Bone, myocardium and muscle tissue. This  acts as  a cofactor for enzymes that could be even 
300 enzymes particularly in enzymes where ATP and energy production are concerned with 
Magnesium is also required for cells  to perform  normal  functions thereby  regulation of 
cellular permeability and improving neuromuscular functions. It is necessary because both the 
production and function of the parathyroid harmone depend on magnesium level. It also causes 
formation of 25-OH D3. Hypomagnesaemia often seen in in diabetic patients, mostly seen in  
those with uncontrolled blood sugar levels. There is also evidence that Increased magnesium 
  
supplements can cause improvement in insulin secretion and action, dyslipidemia, decrease 
thrombotic tendency thereby prevention of endothelial dysfunction and vascular contractility. 
There is a relation between Hypomagnesemia and insulin resistance, where it enhances insulin 
resistance thereby hyperglycemia keeps persisting, and when it is chronic it leads to  
macrovascular and microvascular complications, thereby decrease in magnesium level also 
getting  worsened.                   
The exact pathology process between the DM and decreased magnesium was still unclear 
but there are some studies which proved that magnesium supplementation has shown some 
improvement in the insulin action and also in the carbohydrate metabolism. Since Magnesium 
also takes part in carbohydrate metabolism, it’s deficiency can be seen in diabetes mellitus where 
the both  inadequate nutritional  requirement  and low serum magnesium levels contribute . 
Infact studies have shown that low magnesium levels are recently considered as risk factor for 
hypertension and acute coronary syndrome. With all these evidence in order to study about the 
correlation  between the diabetes and achievement of glycemic control  and also to study about 
the alteration  in serum magnesium levels in those with diabetes mellitus  who are healthy 
controls also to compare the levels of magnesium  in a controlled  and in uncontrolled glycemic 
status in diabetic patients. It also helps to correlate the relation of magnesium to microvascular 
and macrovascular complications in patients with diabetes. 
 
 
 
 
 
  
AIMS AND OBJECTIVES 
 
1. To compare the levels of magnesium in patients with type 2 diabetes mellitus and in non-
diabetic individuals. 
2. To study levels of serum magnesium in controlled and uncontrolled diabetics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
REVIEW OF LITERATURE 
   
  Type 2 diabetes mellitus is a chronic metabolic disorder it becomes on of the major 
health challenge in 21
st
 century 
1. So many modalities of prevention of diabetes and it’s 
complication has been under trial.  
Hypomagnesemia is now become a common feature in diabetes mellitus particularly type 
2. Magnesium deficiency was accepted as a risk factor for type 2 diabetes mellitus in recent 
studies , diabetes itself can cause hypomagnesemia
2
. In some animal study, it shows that 
magnesium has a negative effect on insulin signaling especially in the post receptor signaling. 
Even there are studies which shows that magnesium supplementation usually  gives a 
Improvement in insulin action and also regulates metabolism of carbohydrates
2
. In some studies. 
There is a evidence that magnesium plays a important role in glucose metabolism
3
. 
MAGNESIUM      
In our body magnesium is one of the most abundant cation and where it is largely  seen 
intracellularly  like  potassium. Human  body contains 21 to 28 gm of magnesium
4
 
(approximately 1 mol.) in a average  70 kg of  body weight. Of this 60% are seen in bone,  
skeletal muscle comprises about 20% , 19% of magnesium is found in other cells and 1% of 
magnesium  found in extracellular fluid. It is a eleventh most abundant element in human body 
mass. serum magnesium levels can be normal even if there is a  underlying deficiency , even 
though  there are no proven mechanism to maintain a homeostatic level in blood and also by  
renal excretion of high blood levels. 
 
  
BIOCHEMISTRY 
Since it is an alkaline earth metal, it has chemical properties different from other other 
transition metals. When compared with other transition component and has a relative preference 
for oxygen over nitrogen atoms
5
. There are two major roles for magnesium in bilogical system .  
 Magnesium can interact  with calcium  binding sites on protein and membranes  
 It has the capacity to form chelates due to most important ligands, which is present 
intracellularly like Adenosine Triphosphate (ATP). 
It can catalyse  more than  300 enzymes in our human body. It also act as an coenzyme  
which gain it’s essential in concerning  with cell respiration, pathway of glycolysis and also take 
part in transport of other cations such as  calcium and sodium across transmembrane
6
 . Even the 
activity of Na-K ATPase can depend on serum magnesium level for it’s action .The active site of 
the enzyme like pyruvate kinase and Enolase activity are affected where the magnesium causes 
conformational changes especially during the catalytic process (Na-K ATPase) through by ligand 
binding (ATP-requiring enzymes) and also it promotes aggregation of multi enzyme complexes. 
The magnesium also can affect the permeability characteristics and electric properties of 
membrane. It has a strongly intense 2+ charge, magnesium ions which is predicted to engage 
primarily in electronstatic bonding with negative ions in which charge is a primary determinant 
of bonding strength.
7
 In general there are very few instances in biology can engage in covalent 
bonding.  The most notable example is covalently-bound magnesium in the ring structure of 
chlorophyll. 
There are some other biochemical processes that of magnesium  which are used for the 
synthesis of cholesterol, where Magnesium  ions not only assist in forming the pyrophosphate 
  
bond from Magnesium-ATP in cholesterol precursors. It can  also used  in subsequent 
condensations reaction that give rise to the familiar ring structure of cholesterol
8
. It  is  a 
prominent element  in the nucleus and cytosol where it serves as a crosslinking ion that stabilizes 
DNA and RNA.  Magnesium due to overall architecture of its cell membrane, a property it shares 
with calcium and to a lesser extent  zinc.  Stabilization is brought about by acting as a bridging 
ion between phosphorylated and carboxylated molecules.   
DISTRIBUTION 
Magnesium is considered as the fourth most abundant cation seen in our body and is also 
the second commonest amongst elements which is present intracellularly. The total body content 
of magnesium in human  is approximately 25 g (1.03 mmol)
9
, of which about 55% resides in the 
skeleton. Around 35% of skeletal magnesium are released through channels for maintaining a 
normal level of magnesium both intra and extracellularly
10
. About 45% of the magnesium in our 
body is intracellular. The  magnesium concentration in cells is approximately 1 to 3 mmol/lit. In 
general, when the cell has higher metabolic activity then we can expect it’s magnesium content 
will also to be higher . Most of the magnesium seen in our body  is bounded to proteins and some 
of the negatively charged molecules;at the sametime  80% of cytosolic magnesium is bounded to 
ATP
11
. Significant amount of magnesium were found in the nucleus, cytoplasm,  mitochondria 
and endoplasmic reticulum. Freely available magnesium accounts for only 0.5% to 5.0% of total  
magnesium levels in our body and in this fraction it is  important for enzyme activity
12
. This free 
level of magnesium concentration is maintained by a cotransport system which  changes   the 
rate of magnesium to be extruded and intruded by the cell as magnesium cannot enter the plasma 
membrane . Extracellular magnesium levels  account for only about 1% of the total magnesium 
concentration in our body. The magnesium normal  concentration in our body is around 1.7 to 
  
2.4 mg/dl (0.70-0.99mmol/d)
13
. in that about half of magnesium is available as free ion , 1/3
rd
  is  
associated with proteins (primarily albumin) and 15% complexed with phosphate, citrate and 
other anions. 
TISSUE DISTRIBUTION AND METABOLISM: 
The content of magnesium at birth is around 760mg  and  during 4-5 months of age it is 
approximately  5 g .  During adult the magnesium requirement is high so around 25 gram is 
found  . Among  the  total body  magnesium,  muscles  and  soft tissues comprises about 30-40 
%,  remaining 1 percent is found in extracellular fluid
14
, and some of it is found  in the skeleton, 
where it accounts for up to 1 percent of bone ash.  Magnesium levels are seen abundantly in 
plant,  animal foods,  geochemical  and other  variables 
12
.  Plants which are rich in magnesium 
are   legume seeds, peas, green leafy vegetables beans, and nuts .magnesium contents are much 
rich in food stuff like  some shellfish, spices, and soya flour, where the they contain magnesium 
of more than 500 mg/kg fresh weight
14
.  
Reasonable sources for magnesium are unrefined cereal grains are many highly refined 
flours, tubers, fruits, and fungi and most oils and fats which contribute to the magnesium dietary  
requirement (<100 mg/kg fresh weight) .  other vegetables which have low magnesium content 
are polished rice flour,  Corn flour, cassava and sago flour
15
 . The recommended dietary 
allowance for magnesium in adult is 270-350 mg/day. Normally 1/3
rd
 of ingested magnesium is 
absorbed  through the gastrointestinal tract. But sometimes this may be changing  because 
intestinal absorption of magnesium is opposite to amount of intake of magnesium. 
The malabsorption syndromes can affect intestinal absorption of magnesium which can 
be affected by factors like things that can affect transit time, calcium, phosphate, protein, lactose 
  
or ingested alcohol. There is no evidence regarding Vitamin D affecting  magnesium absorption. 
Now the kidney plays the major excretory pathway for  magnesium so it is considered that 
kidney maintain magnesium homeostasis  thereby maintaining plasma concentrations. When 
there is a  magnesium depletion occurs renal system tries to compensate by decreasing  
magnesium excretion
16
. Kidney excretes only 3 to 6% of the filtered magnesium . whereas 
Around 1/4
th
  of the filtered magnesium is getting  reabsorbed in the proximal convoluted tubule 
and one half of ingested magnesium level are absorbed in the ascending limb of loop of henle 
where as  in the distal convoluted tubule magnesium absorption is usually depending on quantity 
of intake . The renal clearance and plasma concentrations can be  often compared to those of 
calcium, phosphate, sodium and potassium. The hormonal regulation which plays in the renal 
clearance of potassium the same hormonal regulation was seen in magnesium.  
The most part of magnesium is that in plasma (about 60-70%) usually seen as free ions 
whereas sometimes it is seen in the form of various diffusible complexes; especially like protein. 
In children under these ages of six mother’s milk is a only source of magnesium17. Infact there is 
insufficient information to establish an RDA for infants. Gender differences are not seen until 
early adulthood. In Pregnancy and lactation period there should be a modest increase in the 
recommended dietary allowance for magnesium. The intake of magnesium tends to increase as a 
person grows older.   
The homeostasis of magnesium is maintained by three important organ like intestine 
which plays in absorption, the bone it’s also plays in absorption and the Kidneys which causes 
excretion of magnesium levels. Like calcium it gets absorbed in the intestine and usually stored 
in bone material. When there is excess magnesium in our body then kidney and faces tries to 
release by maintaining homeostasis
18
 . Most of the magnesium is absorbed in small intestine and 
  
also some is absorbed in large intestine. The absorption of magnesium is through  small intestine 
is due to a passive process , which can  process either by an gradient which is active  and solvent 
drag. Other mechanism is through  transcellular transporter transient receptor potential channel 
melastatin member (TRPM) 6 and TRPM7
19—these are  related to  persisting transient  
potentially activated receptor  channel
19
 family— they  also have an  role in absorption of 
calcium through intestinal tract. 
Table 1: 
DAILY REQUIREMENTS OF MAGNESIUM: 
 
LIFE STAGE AGE (in years) RECOMMENDED DIETARY 
ALLOWANCE 
MALES 
(mg/day) 
FEMALES 
(mg/day) 
CHILDREN 1  -   3 80 80 
CHILDREN 4  -   8 130 130 
CHILDREN 9 -    13 240 240 
ADOLESCENT 14  - 18 410 380 
ADULT 19  -  30 400 310 
ADULT 30  - 50 420 320 
ADULT >51 420 350 
PREGNANCY 19  -  30 --- 350 
PREGNANCY 30  - 50 --- 360 
LACTATING 19  -  30 --- 310 
LACTATING 30  - 50 --- 320 
 
 
 
  
CLINICAL SIGNIFICANCE: 
The prevalence of  hypomagnesaemia is one of the common entity seen in  Patients who 
are admitted , with a range between 9 to 65%  with highest  incidence  is  observed in intensive 
care units
16
. Recent studies shown that there is a strong association of hypomagnesaemia in 
patients undergone esophageal surgery. Generally critical care patients, magnesium 
supplemented for patient  is insufficient. Drugs were also found to  have been associated with 
depletion of magnesium in our body therefore , making the patients at an very much severe risk  
for clinical  manifestation . It also have been  proposed that in patients  who are admitted  with 
very low magnesium levels , there is a increase in  mortality rate
11
. So magnesium assessment  is 
required  in critically ill patients. One of the best defined manifestation of magnesium deficiency 
is impairment of neuromuscular junction which can present as  hyperirritability, tetany, 
convulsions and electrocardiographic changes.
2
 Magnesium deprivation has also  shown to be 
associated with cardiovascular disease through so many studies which showed epidemiologically 
related evidence that relation between  low magnesium intake to a high incidence of cardiac 
deaths, particularly seen in soft water areas where there is a lowwaterborne magnesium content   
and a very minimal incidence of cardiac deaths is noticed in hard water areas in which the  
content of  magnesium is high. Magnesium depletion also have been linked to hypertension, 
myocardial infarction, cardiac dysrhythmias, coronary vasospasm and premature atherosclerosis. 
Usually reduced magnesium levels is associated with either normal or reduced serum 
calcium concentrations. Hypomagnesemia also may play a role in secondary affect in 
hypocalcemia or calcium deficient tetany
20
. When a case present with hypomagnesemic 
normocalcemic tetany has been described only magnesium supplementation can be given alone. 
There are some cases which present as tetany with normal serum calcium levels  and decreased 
  
serum magnesium levels.
14
 So only calcium administration in tetany will not be given alone if 
there is a evidence of magnesium deficiency then magnesium supplementation should also be 
given. There is a association between decreased serum potassium concentrations (hypokalemia) 
and magnesium deprivation.
21
 Even in unexplained hypokalemia and also in unexplained 
hypocalcemia serum magnesium deficiency to be suspected. 
There are so many condition that have been associated with hypomagnesemia that 
includes  acute pancreatitis, chronic alcoholism,  hypothyroidism, malabsorption,  chronic 
glomerulonephritis, aldosteronism, childhood maturation, lactation,  digitalis intoxication and 
prolonged intravenous feeding.
22
 If there is any disrupt in normal renal conservation of 
magnesium like  renal tubular reabsorption defects, those taking drugs like  chlorothiazides, 
diuretics for congestive heart failure and ammonium chloride also results in hypomagnesemia.  
Hypomagnesemia can also be triggered by conditions which trigger the  increased  
excretion of magnesium in  conditions like  diabetes mellitus, hyperthyroidism, renal tubular  
disorders, another major cause like  hypercalcemia, or aldosteronism or in persons with 
excessive lactation and acute pancreatitis due to Compartmental  redistribution of magnesium  
will be seen in patients with pancreatitis patients
18
. Diagnosis of chronic hypomagnesaemia will 
be difficult because there will be always maintenance of magnesium with negative balance 
overtime. There is a equilibrium which is mostly seen in most of tissue pools that serum 
concentration of magnesium is usually maintained by magnesium available from bone.  
           
  
  
Table 2:                    
CAUSES FOR HYPOMAGNESEMIA 
PRIMARY NUTRITIONAL  
DISTURBANCES 
 Inadequate intake  
 Total parenteral nutrition  
 Refeeding syndrome 
GASTROINTESTINAL DISORDERS 
 Intestinal absorbtion defects  
 Malabsorption syndromes  
 Chronic  diarrhoea  
 Chronic  nasogastric suction 
 Acute Pancreatitis  
  Ingestion phosphate cellulose 
HORMONE RELATED DISORDERS 
 Hyperparathyroidism  
 Hypoparathyroidism  
 Grave’s disease 
 Aldosteronism-primary 
 Bartter’s syndrome  
 Diabetes acute complications  
 Alcoholic with dehydration 
CATABOLIC CONDITION 
 Epinephrine excess 
 Acute necrotising pancreatitis  
 After  correction of respiratory acidosis  
 Multiple  blood transfusion 
CHRONIC ETHANOL CONSUMPTION 
 Alcohol withdrawl syndrome 
 Alcohol dependent syndrome 
  
INCREASED RENAL EXCRETION 
 Idiopathic  
 Post  renal transplantation  
 Cyclosporine administration  
 Amikacin (Aminoglycoside) theraphy  
 SIADH  
 Diuretic administration  
- Loop diuretics   
- Ethacrynic acid administration 
- Acetazolamide theraphy 
- Hydrochloro thiazides  
- Recovery from acute tubular 
necrosis  
 Theophylline toxicity 
OTHER CAUSES 
 Stress 
 Increased period of  lactation, heat,  
exercise  
 Burns with high grade 
 Bypass surgery  
 Iatrogenic  
 
  
  
Table 3: 
CLINICAL SIGNS OF HYPOMAGNESAEMIA: 
NEUROMUSCULAR 
 Weakness    
 Tremor    
 Muscle fasciculation  
 Positive Chvostek’s sign 
 Positive Trousseau’s sign 
 Dysphagia 
CARDIAC 
 Arrhythmias  
 ECG changes:   
Depression of ST segment              
 Flattening of T waves              
 QT/QTc prolongation  
Enhanced atrial and ventricular 
excitability 
CENTRAL NERVOUS SYSTEM 
 Depression 
 Agitation 
 Psychosis 
 Nystagmus 
 Seizures 
METABOLIC 
 Hypokalaemia 
 Hypocalcaemia 
 
  
  
LABORATORY ASSESMENT OF MAGNESIUM NUTRITION: 
Serum or plasma magnesium concentration  
   Plasma level of magnesium monitoring can provide an appropriate support for diagnosing  
magnesium deficiency. 
2
 Hypomagnesemia in serum level can predict whether  there is a 
evidence of low magnesium levels, but sometimes it’s normal report will not always exclude 
magnesium deficiency always. The serum level of magnesium level shows found correlation 
only with interstitial fluid when compared to any other tissue pools of magnesium. 
Magnesium concentration in muscle: 
Muscle usually contains approximately 27% of total magnesium. Thus tissue plays a 
important role for magnesium status assessment
5
. Needle biopsy is done to determine the 
magnesium concentration in muscle, but this procedure is invasive so requires special skills and 
the assay is tedious. 
Mononucleated white cell magnesium concentration: 
Intracellular magnesium is usually measured by using index of  mononucleated white cell 
(MNC) magnesium concentration which  has been proposed as a possible index
7
 . In humans 
magnesium concentrations in MNCs there is no correlation between serum or erythrocyte 
concentrations but there are  some studies which showed a positive  correlation between the 
magnesium concentration of MNC and muscle
23
. 
 
The magnesium content of MNCs is reportedly 
a better indicator of cardiac arrhythmias associated with magnesium deficiency than that of 
serum magnesium level. 
  
  
Magnesium retention after acute administration: 
There are oral and intravenous magnesium preparation available in which loading tests have 
been described and they are mostly used in clinical practice for diagnostic purpose rather than 
intracellular measurements
3
. In normal individuals within 24 to 48 hours after administration 
magnesium balance is maintained by excretion of essentially all injected magnesium in urine, 
whereas persons with a magnesium deficit the kidney tries to retain a significant proportion of 
the administered  magnesium. In this procedure 30 mmol of magnesium in 500 ml of 5% 
dextrose is administered intravenously over 12 hours
24
. A 24 hour urine is  collected  before 
starting the magnesium  infusion.when there is a retention of less than 30% of infused 
magnesium suggests magnesium depletion is unlikely. Patients who are undergoing this test 
should have normal functioning kidney, there should not be any intake of medication that affects 
renal excretion of magnesium and also does not have disturbances in cardiac conduction or 
advanced respiratory insufficiency. 
DITERMINATION OF MAGNESIUM  
Methods 
Measurement of  Serum magnesium has been done by a wide variety of techniques including 
precipitation, titrtration, fluorometry, photometry, flame emission spectroscopy and AAS.
25
 
Methods used earlier are ammonium phosphate to quantitatively precipitate magnesium which 
could then be determined gravimetrically or by analysis of phosphate in the precipitate. The 
precipitation of magnesium by 8-hydroxyquinolone is the basis for the measurement of 
magnesium by various techniques. Titrimetric methods have been reported using EDTA with an 
indicator eriochrome black T in a manner analogous to the titrimetric method described for 
calcium
4
. Flame emission spectroscopy has been used despite the fact that magnesium is a poor 
  
emitter at low temperature and the large quantity of sodium, potassium and phosphate interfere. 
A number of flourometric methods have been used.  
Enzymatic methods have now been developed with hexokinase or other enzymes that use 
Mg-ATP as substrate. The rate of this reaction is dependent on the concentration of magnesium 
in the sample. Coupling hexokinase glucose-6- phosphate-dehydrogenase allows the reaction to 
be monitored at 340 nm with the formation of NADPH. 
 
Today photometric methods are more 
commonly used by clinical laboratories, although AAS considered the reference method is also 
used by some laboratories.  
Photometric methods 
A metallochromatic indicators or dyes which changes colours that are selectively 
considered as binding site for magnesium and have been proposed to measure magnesium it in 
biological samples. Eriochrome black T, chrome fast blue G and titan yellow are of historical 
interest they are not widely used today
17
. According to the  American college pathologists where 
they did the comprehensive chemistry survey on 1991, Where calmagite was considered and 
used by 43% laboratories for magnesium determinations, followed by methylthymol blue and a 
formazan dye, each with 24% magon at 7% and AAS ay 1%. Calmagite a metallochromatic 
indicator which forms a coloured complex when combined with magnesium in alkaline solution 
which is measured at 530-550nm
26
. A specific calcium chelating agent, EGTA (ethylene glycol-
O,O-bis(2-aminoethyl)-N,N-tetra acetic acid, is added to prevent interference by calcium. 
Potassium cyanide is added to avoid formation of heavy metal complexes. Polyvinylpyrrolidone 
and surfactants are included to reduce interference from  protein and lipemia. Methylthymol blue 
  
forms a blue complex with magnesium which is measured around 600 nm. EGTA is generally 
added to avoid  interference by calcium.  
Magon, or xylidyl blue (1-azo-hydroxy-3-[2,4-dimethylcarboxanilideo]-naphthalene-1-
[2-hydroxybenzene], binds magnesium in alkaline solution causing a spectral shift and forming a 
red complex.
 
Calcium and protein interference is eliminated by EGTA and dimethyl sulfoxide 
respectively.
27
 A formazan dye (1, 5-bis[3,5-dichloro-2-hydroxyphenyl]-3-formazan carbonitrile) 
forms a complex with magnesium at alkaline Ph which has been measured at 630 nm by thin 
film reflectance photometry. The thin film reflectance method is unaffected by icteric, lipemic 
and hemolysed specimens. Elevated calcium levels cause a small but measurable overestimation. 
Atomic absorption spectrometry 
Although neutron activation with magnesium is the definitive method for magnesium 
analysis, clinical laboratories use AAS as the reference method. Even though AAS 
can provide greater accuracy and precision it is not frequently used by most clinical laboratories 
for routine determination of magnesium
16
. Magnesium done here determined by AAS which is 
obtained by diluting the specimen collected in a standard solution which contains lanthanum 
hydrochloride is added inorder to stop any anionic disturbance  including phosphate and some 
other include  metal
28
. The viscosity is reduced by dilution and it is important thereby confirming  
that absorptive capacity for aqueous calibrators and other things to be compared. The specimen 
is usually aspirated  and aspirated one  is sent  into an flame  which contains airacetylene because 
so that magnesium ions which were grounded can absorb light from a magnesium hollow lamp 
(285.2nm)
19
 placed within the calibrator . Absorption of light at particular nanometer  is 
considered as a directly proportional to the magnesium atoms which were grounded  in the 
flame. 
  
Free magnesium 
Free magnesium has been determined in whole blood, plasma, or serum by ion selective 
electrode neutral carrier ionophores. 25 Further improvements in ion selective for magnesium are 
required in order to increase the availability of free magnesium determinations.  
Specimen 
Serum is the preferred specimen but heparinised plasma may also be used. Other 
anticoagulants such as citrate, oxalate and EDTA are not acceptable because they form 
complexes with magnesium. Magnesium is considered to be stable in serum for days at 4 C and 
for months when frozen, provided evaporation and lyophilization are avoided. As soon as Serum 
or plasma is collected it should be separated from the clot or red blood cells all these to be done 
to avoid increased levels due to cell leakage. Because erythrocytes used to contain higher levels 
of magnesium when compared to  plasma or serum hemolysed samples are unacceptable. 
Interference by icterus or lipemia depends on the methods and use of dialysis, bichromate 
analysis or blanking. Lipemic specimens should be ultracentrifuged. Interference in photometric 
methods may be overcome with EDTA blanking
12
 
Urine specimens should be collected in HCl, 20 to 30 ml of 6 mol/L for 24 hours 
specimen, to prevent precipitation of magnesium complexes. As with calcium, if acid must be 
added after collection, the entire specimen must be acidified and heated. Collection of the 
specimen in acid to prevent precipitation is recommended.  
  
  
Reference Interval: 
 The reference interval for serum magnesium is approximately considered as 1.7 to 2.2 
mg/dL (0.70 - 0.99 mmol/L). serum Erythrocytes have been tend to have magnesium levels 
probably  three times when compared to those of serum. There are some Interconversion factors 
used to determine the units and also to show levels of  serum magnesium  are :  
mmol/L= mEq/L X 0.5 = mg/dL X 0.14  
mEq/L = mmol/L X 2 = mg/dL X 0.82  
mg/dL = mEq/L X 1.22 = mmol/L X 2.43  
 
TREATMENT 
 Underlying cause to be treated 
 In healthy individuals with mild hypomagnesemia oral supplementation of magnesium is 
indicated 
 Oral supplementation is also indicated in persons with inadequate intake or disorders of 
intestine and excess urinary excretion of magnesium
29
 
ORAL SUPPLEMENTATION  
- 2 ml of 50% magnesium sulfate heptahydrate every 6
th 
hourly- 1
st 
day  
- 1 ml of 50% MgSO
4 
7H
2
O for following 3 – 4 days 
 In persons with cardiac arrythymia and severe hypomagnesemia intravenous 
administration of magnesium sulphate is indicated. 
  
 In Cardiac arrhythmias  patients with nausea and vomiting – IV Magnesium therapy 4.2 
mmol Mg SO
4 
(1 gm) every 6 hours.  
 In  torsade de pointes or ventricular arrhythmias – 8 mmol of Mg SO
4 
over 1 to 2  
minutes followed by infusions (8 to 12 mmol/hour for 4 to 8 hours and smaller doses 
thereafter). 
 
HYPERMAGNESEMIA 
The renal system plays a important role  in maintaining  magnesium homeostasis, so in 
case of patients with advanced chronic kidney disease
11
, here the compensation becomes  
impaired and there by hypermagnesaemia may develop. In Symptomatic hypermagnesaemia  
causes could be due to  increased oral intake  of either could be magnesium salts or rapid use of 
magnesium-containing drugs like  liquid paraffin, lactulose and alluminium hydroxide,  these 
occur when particularly when used in combination especially in the aged persons
16
 . In eclampsia 
hypermagnesaemia can  be iatrogenic, when high doses of magnesium sulphate is routinely used  
for treating seizure even as an infusion and also as  a  prophylaxis in eclampsia. 
Other causes for hypermagnesemia  
1) Rhabdomyolysis 
2) Adrenal insufficiency  
3) Familial benign hypocalciuric hypercalcemia 
4) Near drowning in the dead sea (in Jordon)  
 
 
  
Clinical features:   
 Facial parasthesia  
 Sedation  
 Hypoventilation with respiratory acidosis  
 Diminished  deep tendon reflexes  
 Weakness of muscle 
 Low blood pressure 
 Bradycardia  
 Areflexia, coma and respiratory paralysis occurs at higher levels  
TREATMENT: 
 Symptomatic hypermagnesemia can be reversed by calcium  gluconate infusion  
 Normal saline and furosemide helps in renal excretion of magnesium 
 Hemodialysis is indicated in severe symptomatic hypermagnesemia 
 
  
  
Table 4: 
 
SERUM MAGNESIUM 
LEVELS (mmol/L) 
CLINICAL MANIFESTATION  AND   ECG CHANGES 
2.1–2.4 GIT MANIFESTATION : 
 Paralytic ileus 
ECG CHANGES: 
 Bradycardia  
 
2.5–4.0 NEUROLOGICAL MANIFESTATION: 
 Absent  or diminished reflexes , weakness of muscle , 
 Slurring of  speech, tiredness  
CIRCULATORY-RESPIRATORY-GIT MANIFESTATION: 
 Low blood pressure, nausea, decreased uterine tone upon 
 magnesium infusion ,periodic bowel paralysis 
ECG CHANGES: 
 Tachycardia, T-wave abnormalities , prolonged QT-time 
3.7–4.9 NEUROLOGICAL MANIFESTATION: 
 Drowsiness, absent reflexes, quadriparesis. 
CIRCULATORY MANIFESTATION: 
 Hypotension  
 
 
5.0–6.95 NEUROLOGICAL MANIFESTATION: 
 Complete tiredness , slurring of speech, worsening muscle 
 weakness 
CIRCULATORY-RESPIRATORY- MANIFESTATION: 
 Hypotension , increased respiratory rate, respiratory arrest 
ECG CHANGES: 
 Atrial fibrillation , QT prolongation, sinus tachycardia, 1st 
 degreeAV-block, bradycardia  
  
Up to < 7.65 and 7.3 NEUROLOGICAL MANIFESTATION: 
 Paralysis of the limbs 
CIRCULATORY-RESPIRATORY- MANIFESTATION: 
 No respiratory arrest, slight decrease of blood pressure 
ECG CHANGES: 
 Sinus arrhythmia, slight alterations in ventricular action (T-
 wave, ST, R abnormalities, prolonged PR interval) 
>8.9–10.65 NEUROLOGICAL MANIFESTATION: 
 Coma, pseudocomatose state, central brain-stem herniation 
 syndrome, non-fatal neuromuscular blockade 
CIRCULATORY-RESPIRATORY- MANIFESTATION: 
 Profound hypotension, cardiopulmonary non-fatal arrest  
 cardiovascular  collapse at 25 mg/dL 
ECG CHANGES: 
 Prolonged QT interval, bradycardia 
Up to 13. 5 CIRCULATORY-RESPIRATORY- MANIFESTATION: 
 Respiratory depression, apnoe, cardiopulmonary arrest 
ECG CHANGES: 
 Non-fatal refractory bradycardia 
 
DIABETES MELLITUS 
 It is a common  metabolic disorder  encountered  in India which sharing  the same 
phenotyping  of serum hyperglycemia. There are several different types of diabetes mellitus 
which are caused by complex  features of both  genetics and environmental factors.Diabetes is 
becoming one of the most epidemic of the 21st century.
29
 Type 2 diabetes mellitus , which is 
more prevalent (more than 90% of all diabetes cases) among all diabetes  and it is usually 
considered as a the  main driver of the diabetes epidemiology ,which now at present usually 
affects approximately 5.9% of the world's adult population and in this population among 80% of 
  
the diabetes are total in developing countries. Now diabetes epidemic is more pronounced in 
India as per World Health Organization (WHO) reports which shows information  that around 32 
million people had been diagnosed as diabetes in the year 2000
30
. 
The International Diabetes Federation (IDF) has estimated that number of diabetic 
subjects to be around 40.9 million in India and this can further set to rise to as much 69.9 million 
by the year 2025 
DEFINITION 
It is a  variable disorder in which the carbohydrate metabolism is altered which can be  
caused by a combination of hereditary and environmental factors
8
. But it is  usually characterized 
by inadequate production or impaired  utilization of insulin by l tissues, by excessive urinary 
excretion , by increased levels of  sugar in the blood and urine, and all these can cause  thirst, 
hunger, and weight loss. 
There are some independent  factors which contribute to hyperglycemia is inadequate   
insulin Production , impairment  in utilization of glucose and increased glucose production in 
body
7
 . All these contributing factors are formed depending on specific  etiology of diabetes 
mellitus. The metabolic dysregulation usually starts occurring gradually  in diabetes mellitus 
finally which causes secondary pathophysiological changes in multiple organ systems there by 
resulting in both macrovascular and microvascular complications, including diabetic 
nephropathy, diabetic neuropathy, and diabetic retinopathy. 
Pathology behind diabetes  ranges from auto-immune destruction of the beta cells of the 
pancreas due to which there is a  consequent insulin deficiency to abnormalities in metabolism of 
carbohydrate, fat and protein resulting in diabetes and in some patient there is a deficient action 
  
of insulin on target tissues
28
 since there is a  deficient insulin action which usually results from 
insufficient  insulin secretion and/or decreased tissue responses to insulin at one or more points 
resulting  in the complex pathways of hormone action.  
Long term complications of diabetes include retinopathy along with Gradual loss of 
vision, nephropathy which can eventually lead to renal failure( ESRD – end stage renal disease), 
peripheral neuropathy associated with risk of foot ulcers which can progress  to amputation, and 
also Charcot joints can be seen 
31
; and autonomic neuropathy causing orthostatic hypotension, 
gastrointestinal paresis, genitourinary symptoms, cardiovascular symptoms(chest pain) and 
sexual dysfunction (impotence). Patients with diabetes have an increased incidence of 
atherosclerotic either involving cardiovascular, peripheral vascular and cerebrovascular 
disease
32
. Hypertension abnormalities due to  lipoprotein metabolism and periodontal disease are 
often found in people with disease. 
The classification of diabetes is based on pathogenic process. It is generally classified in 
to two broad categories type 1 DM and type 2 DM
8
. Other than these two etiologies of DM 
include specific genetic effects, insulin production / action, metabolic abnormalities that can 
impair insulin secretion, mitochondrial abnormalities and a number of conditions that impair 
glucose tolerance.                        
 
 
 
  
 
ETIOLOGICAL CLASSIFICATION OF DIABETES:
Reference American Diabetes Association
(2011) 
I. Type 1 diabetes (beta cell destruction, usually leading to absolute insulin deficiency) 
                        
                        a. Immune mediated 
b. Idiopathic 
II. Type 2 diabetes (may range from predominantly insulin resistance with relative
insulin deficiency to predominantly secretory defect with insulin resistance) 
III. Other specific types: 
A. Genetic defects of beta cell function 
1. Hepatocyte nuclear transcription factor (HNF) 4α (MODY 1)
2. Chromosome 7, glucokinase (MODY – 2) 
3. Chromosome 12 HNF – 1 α (MODY – 3) 
4. Insulin promoter factor-1 (IPF-1 : MODY-4)
  
 
5. HNF-1   (MODY-5)
6. NeuroD1  (MODY-6)
7. Mitochondrial – DNA
8. Subunits of ATP – sensitive potassium channel.
9. Proinsulin or insulin
B. Genetic defects in insulin action
1. Type A insulin resistance 
2. Leprechaunism 
3. Rabson – mendenhall syndrome 
4. Lipodystrophy syndrome 
C.  Disease of the exocrine pancreas 
1. Pancreatitis 
2. Trauma
3. Neoplasia 
4. Cystic fibrosis 
5. Hemochromatosis 
6. Fibrocalculous pancreatopathy 
7. mutations in carboxyl ester lipase
D. Endocrinopathies :
1. Acromegaly 
  
 
2. Cushing’s syndrome 
3. Glucagonoma 
4. Pheochromocytoma 
5. Hyperthyroidism 
6. Somatostatinoma 
7. Aldosteronoma 
8. Others. 
E. Drug or Chemical related 
1. Vacor 
2. Pentamidine 
3. Nicotinic acid 
4. Glucocorticoids 
5. Thyroid hormones 
6. Diazoxide 
7. Beta-adrenergic agonists 
8. Thiazides 
9. Dilantin 
10. Alpha- interferon 
11. Others 
F. Infections 
1.      Congenital 
Cytomegalovirus
  
 
1.      Coxsackie virus
G. Uncommon factors of immune mediated diabetes 
1. Stiff Man syndrome 
2. Anti – insulin receptor antibodies 
3. Others 
H. Other genetic syndromes sometimes associated with diabetes 
1. Down’s syndrome 
2. Klinefelter’s syndrome 
3. Turner’s syndrome 
4. Wolfram’s syndrome 
5. Friendrich’s ataxia 
6. Huntington’s chorea 
7. Laurence- Moon Biedl syndrome 
8. Myotonic dystrophy 
9. Porphyria 
10. Prader- willi syndrome 
11. Others 
IV. Gestational Diabetes mellitus (GDM) 
  
TYPE 1 DIABETES MELLITUS 
This is a form of diabetes where there is a autoimmune pancreatic β- cell destruction and 
is characterized by absolute insulin deficiency. American diabetes association has differentiated 
type 1 diabetes mellitus as type 1A and type 1B.
13
 It is mostly seen in children. Type 1 is 
immune mediated and type 1 are other forms of diabetes associated with insulin deficiency.  The 
current best criteria for diagnosis of type 1A diabetes is the presence of anti-islet auto antibodies 
which can be measured with highly specific (and reasonably sensitive) autoantibody radio 
assays. 
33
The presence of auto antibodies with assays is usually defined as positive if  fewer than 
1 of 100 control subjects  where specificity ≥99% is reasonably diagnostic tool for type 1A 
diabetes. 
More than 90% of children who are presenting with diabetes express one of four 
measured anti-islet auto antibodies. In contrast, some half of black or Latin American children 
lack any autoantibody
34
. But these children most of them appear to have an early age at onset of 
type 2 diabetes mellitus and some other have attendant risk factors like obesity, and many lack 
human leukocyte antigen (HLA) alleles associated with type 1A diabetes. 
 
 
 
 
 
 
 
 
 
  
Table 5: 
Differential diagnosis of type 1 A diabetes 
34
: 
Types of 
diabetes 
Anti-Islet Auto 
antibodies 
Genetics Comments 
TYPE 1A Positive >90% HLA 30-50% DR3 and DR4 
 
HLA 90% DR3 or DR4 
HLA < 3% DQBI*0602 
90% non-Hispanic white 
children 
50%  black children 
50% Latin American 
children 
TYPE 1B    Negative  Unknown Rare in whites 
TYPE 2    Negative   Unknown If Ab+ , likely LADA, and 
HLA is similar to type 1A  
OTHER Negative  MODY mutation and Other 
syndromes 
 
 
Reference: Williams book of endocrinology 
 
 
 
 
                 
 
 
 
 
 
 
 
 
  
Pathogenesis of type 1 diabetes mellitus 
Islet cell normal in function 
 
Probably viral infection affecting pancreatic beta cells 
 
Pancreatic beta cell secretes  interferon-α 
 
Hyper expression of class 1 MHC antigenic within islets 
 
INSULITIS 
 
Selective and sustained destruction of beta cells 
(Glucagon secretion preserved) 
 
Insulin-deficient islet 
 
 
                                                                        
  
 
Reference: William’s text book of endocrinology 
 
  
  
  
Hypothetical stages in development of type 1A diabetes mellitus as beginning with genetic 
susceptility and they ending in complete beta cell destruction. 
Type 1 diabetes mellitus are previously referred as juvenile-onset diabetes. It is usually 
diagnosed in childhood, sometimes in  adolescence age group, or now cases in early adulthood 
are seen
34
 . Eventhough the onset of type 1 DM is seen in much earlier life (childhood life), 
some 50% of patients with new-onset type 1 DM are seen in age older than 20 years of age. 
Usually the onset of type 1 diabetes mellitus  starts in children probably around 4 years of age or 
older with the peak incidence  at 11-13 years of age.  Now a day’s incidence is relatively high in  
people of around  30s and early  40s, but in these people the disease tends to be less 
aggressively
33
 . This type of slower-onset adult form of type 1 DM is referred to as latent 
autoimmune diabetes of the adult (LADA). In this condition there is a risk of development of 
antibodies (anti-islet) in relatives of patients with type 1 DM generally decreases with increasing 
age
29
. This gives guidance for annual screening for antibodies in relatives who are  younger than 
10 years who have positive family history of diabetes and 1 additional screening  should be done  
during adolescence
35
. Type 1 DM is more commonly seen in males when compared to females. 
It is comparatively uncommon among Asians.  
The classical symptoms of type 1 diabetes mellitus include increased thirst, increased 
frequency of micturition , polyphagia and unexplained weight loss
36
 Others include fatigue, 
nausea ,blurring of vision. Rarely some patients initially present with diabetic ketoacidosis. All 
these symptoms could be sudden in onset. Type 1 diabetes mellitus patients will lose weight, 
despite normal or increased appetite it is due to water depletion and a majority of catabolic state 
occurring in the body with reduced glycogen storage , proteins, and triglycerides. This Weight 
  
loss is usually once treatment is initiated. Since type 1A diabetes mellitus patients are immune 
mediated they are sometimes associated with some auto immune disease also. 
Table 6: 
 
 
Disease Auto antibody Disease prevalence 
(%) 
Type Percentage (%) 
Addison’s disease 21-Hydroxylase 1.5 0.5 
Celiac disease Transglutaminase  12 6 
Pernicious anemia Parietal  21 2.6 
Thyroiditis or Grave’s 
disease 
Peroxidase or  
thyroglobulin  
25 4 
  
 
 
 
WHO CRITERIA:
    Fasting blood glucose                             ≥7.0mmol/l (126mg/dl)
    Post prandial glucose                             ≥11.1mmol/l (200mg/dl)
      (2 hrs after meal)
Impaired Glucose Tolerance (IGT):
    Fasting plasma glucose                             <7.0mmol/l (126mg/dl)
    Post prandial glucose                                  ≥7.8 and <11.1mmol/l
     (2 hrs after meal)                                 (140mg/dl and 200mg/dl)
Impaired Fasting Glucose (IFG) :
   Fasting plasma glucose                                 6.1 to 6.9mmol/l
                                                                          (110mg/dl to 125mg/dl)
   Post prandial glucose                                    <7.8mmol/l (140mg/dl)
    (2 hrs after meal)                                 
AMERICAN DIABETES ASSOCIATION CRITERIA:
    Fasting blood glucose                             ≥7.0mmol/l (126mg/dl)
    Post prandial glucose                             ≥11.1mmol/l (200mg/dl)
      (2 hrs after meal)
             HBA1C                                           ≥6.5%
    Random blood glucose                            ≥11.1 mmol/L (200 mg/dL)
  
Table 7: 
DIFFERENTIATION BETWEEN TYPE 1 DM AND TYPE 2 DM: 
              TYPE 1  DM               TYPE 2  DM 
Etiology Auto immune destruction of pancreatic 
beta cells 
Insulin resistance with 
Inadequate beta cell function 
to compensate 
Insulin levels Absent or negligible Typically higher than normal 
Insulin actions Absent  or negligible Decreased  
Insulin resistance Not part of syndrome but may be present 
(eg: in obese patients ) 
Yes  
Age of onset  Typically < 30 years >40 years  
Acute 
complications 
Diabetic ketoacidosis Wasting Hyperglycemic non ketotic 
hyperglycemia, coma 
Chronic 
complications 
Diabetic neuropathy 
Diabetic retinopathy 
Diabetic nephropathy 
Peripheral vascular disease 
Coronary artery disease 
Same as type 1 DM 
Pharmological  
interventions 
Insulin  No. of drug classes are 
available including insulin if 
other therapies fall 
Prognosis    
 
 
 
 
 
  
TYPE 2 DIABETES MELLITUS 
Type 2 diabetes mellitus is a mostly predominant form  in worldwide comprising about 
90% globally
29
. It has become one of the most important world health problems. It usually 
begins in middle age or after 40 years of age. It is mostly seen in obese patients and now onset 
of type 2 diabetes mellitus is rising dramatically. Sex, age and ethnic plays a most important risk 
factors in onset of diabetes mellitus. Insulin resistance is a most pathophysiology of type 2 
diabetes mellitus, that is usually seen in liver and peripheral tissue primarily muscle and adipose 
tissue
16
.  Due to insulin resistance there will be increased amount of insulin may be needed to 
keep normoglycemic status. In type 2 diabetes mellitus, the pancreas initially will be able to 
produce increased amount of insulin quantity there by resulting in hyperinsulinemia condition. 
This hyperinsulinemia condition will be able to compensate the insulin resistance initially so 
these patients may not able to meet diagnostic criteria for diabetes mellitus. After some period 
the beta cells started declining and increased insulin levels will not be sufficient to compensate 
the insulin resistance thereby resulting in clinical diabetes. 
Thus insulin production in type 2 diabetes mellitus patients are considered as ―relative ― 
insulin insufficiency. Another confounding factors include inability to suppress the glucagon 
production particularly in postprandial state which further increases glucose production from 
muscle and liver
5
. The pathophysiology abnormalities include ranging from predominantly 
predominant insulin resistance  and insufficiency of relative insulin secretion to predominant 
insulin secretory insufficiency there by resulting in absolute reduction in insulin production. 
Type 2 diabetes mellitus should not be seen only from it’s impact on glucose metabolism37 it is 
also a part of constellation of other conditions like hypertension, dyslipidemia, abdominal 
obesity and hypercoagulability are generally reffered to as ― metabolic syndrome‖22. Obesity 
  
itself contributes to risk factor for insulin resistance in type 2 diabetes mellitus and the 
distribution of obesity is abdominal.  
 
 
 
 
 
 
                        MAJOR RISK FACTORS FOR TYPE 2 DIABETES MELLTUS
  Overweight (BMI ≥25 kg/m2) 
    
  Physical inactivity 
    
  First-degree relative with diabetes 
     
  Member of a high-risk ethnic population (e.g., African American, Latino, Native American)
                              
  Female with a history of delivering a baby weighing >9 lb or diagnosis of GDM 
     
  Hypertension (≥140/90 mm Hg or on therapy for hypertension) 
     
  HDL cholesterol level <35 mg/dL (0.90 mmol/L) or triglyceride level >250 mg/dL (2.82 mmol/L)   
     
  Female with polycystic ovary syndrome 
  Hemoglobin A1c ≥5.7%, impaired glucose tolerance, or impaired fasting glucose on previous testing
    
  Other clinical conditions associated with insulin resistance (e.g., severe obesity, acanthosis nigricans)
  History of cardiovascular disease 
  
ENVIRONMENTAL FACTORS 
LIFE STYLE 
Overeating, especially when combined with obesity are more  associated with risk of 
Developing  type 2 diabetes
18
. Obesity probably acts as a diabetogenic factor (through which 
there is a increasing resistance of tissues to the action of insulin) in those person who are  
genetically predisposed to develop type 2 diabetes
18
. Most distribution pattern of obesity is 
abdominal where there will be additional pounds of adipose tissue thereby increasing insulin 
resistance. In recent years young people with obesity are more prone for development of type 2 
diabetes mellitus. 
AGING 
Type 2 diabetes mellitus is more common after 40 years of age. In most of the people 
glucose tolerance decreases with age.  
NUTRTION 
There is a change in diets of many ethnic groups which have become westernized 
nowadays can contribute to increased incidence of type 2 diabetes mellitus. High calorie intake 
and increased fat content of meals are most etiologic factors. Reduced fiber intake has also been 
suggested as a risk factor as high fiber diets reduces the incidence of diabetes. 
 
 
 
 
  
PATHOPHYSIOLOGY AND HISTORY RELATED TO TYPE 2 DIABETES 
MELLITUS 
In type 2 diabetes mellitus there will be a gradual increase in insulin resistance. At this 
time pancreas will increase insulin output and normoglycemia is maintained. Over time the 
capacity of pancreas to secrete enough additional insulin started decreasing. This decline usually 
begin as many years prior to the diagnosis of type 2 diabetes
16
. There is also a reduced 
suppression of glucagon in postprandial state which causes increase in endogenous glucose 
production that’s further contributing to postprandial hyperglycemia.  
When the insulin secretion is enough to maintain the insulin resistance normoglycemia is 
maintained. If excess insulin secretory capacity started declining, mild hyperglycemia develop
29
. 
Even though when mild hyperglycemia develops diabetes is diagnosed but due to the lack of 
symptoms there is a delay in discovery of disease. If the diagnosis is made during this time then 
life style intervene can be done to prevent the diabetes and it’s progression. 
When diabetes is diagnosed initially there will be insulin resistance which is more 
peripheral where adipose tissue and muscle is involved. Thereby reflecting the decrease in 
postprandial glucose uptake. At the same time in beta cell there will be loss of first insulin phase 
release. Generally first phase release of insulin occurs after 15 minutes of carbohydrate intake. 
Where as second phase of insulin release represented as a newly manufactured insulin which 
begins after first phase subsided.  This second phase last longer and gives sustained 
carbohydrate coverage for remainder. 
Due to the loss of first phase of insulin release, postprandial glucose rises significantly. 
Lack of glucagon suppression also promotes production of endogenous glucose. In these patients 
  
second phase insulin release is maintained which leads to greater amount of insulin release after 
a high postprandial glucose level
31
. This is because muscle is the main source of glucose uptake 
after meals. During this period more insulin is needed to drive the glucose in to muscle cell and 
fat cell. Insulin also suppress the liver output of glucose by inhibiting gluconeogenesis. This 
higher insulin level can cause drop in blood glucose level 3 to 5 hours after a meal and 
hypoglycemia symptoms can occur.  As the glucose level increases, glucose toxicity can occur
2
. 
The glucose toxicity is due to paradoxical effect of hyperglycemia even on insulin production 
and action. Overtime insulin secretary capacity is blunted, elevation of glucagon levels occur 
and insulin resistance also increases.  
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INSULIN RESISTANCE 
 Hepatic and peripheral  
 Insulin stimulated (post-prandial) glucose uptake impaired, especially in skeletal muscle.  
INCREASE GLUCOSE 
 Enhanced hepatic glucose output, impaired peripheral utilization  
  
PATHOPHYSIOLOGY OF TYPE 2 DIABETES MELLITUS 
 
 
 
  
  
COMPARISION OF NORMAL PHYSIOLOGICAL HORMONAL RESPONSE TO 
FASTING AND POSTPRANDIAL GLUCOSE: 
 
 
 
 
 
  
When hyperglycemia begin to develop , the degree of insulin resistance reaches plateau. 
From this point most of the patients maintain a static degree of insulin resistance, sometimes it 
vary depending upon significant changes in food intake, physiological stress, glucose toxicity, 
activity level and glucose sensitizing medications
7
. From this point the further progression 
causes decline in beta cell function.   
During early stages of beta cell dysfunction, abnormalities in postprandial glucose levels 
are seen. Fasting glucose can be more significantly elevated than postprandial because of 
multifactorial such as dawn phenomenon where there will be lack of eating to stimulate the 
insulin secretion by increasing hepatic insulin resistance and decreasing insulin secretion. Even 
though fasting glucose are elevated it is insufficient to normalize glucose levels. When 
preprandial ( particularly fasting ) glucose levels remain under 200mg/dl and also HbA1c levels 
also under 9% then oral anti-diabetic drugs can provide adequate glucose control targeting both 
pre and postprandial hyperglycemia
38
. Whereas when fasting glucose levels are at or above 
00mg/dl then it indicates that endogenous insulin production is dropping down and glucose 
control can be sustained only with exogenous insulin supplementation. Longer duration of 
diabetes also suggest exogenous insulin supplementation may be needed.  
  
  
 FASTING HYPERGLCEMIA:       
Elevated fasting glucose levels are due to one of the following 
 Insufficient quantity of overnight insulin  
The dawn phenomenon 
There is a increase in amount of insulin requirement during latter part of sleep cycle and 
due to circadian changes in anti-insulin hormone levels ( probably growth hormone)
6
. 
 There is a insufficient duration of overnight insulin action 
The somogyi effect 
Here the body tends to react to extremely low blood sugar (hypoglycemia) by 
overcompensating, thereby  resulting in high blood sugar
39
. The Somogyi effect, also known as 
the ―rebound‖ effect, which was named after  the researcher Michael Somogyi, who first 
described it this phenomenon .When blood glucose levels drops, the body tries to compensate by 
releasing counter regulatory hormones such as glucagon and epinephrine
39
. All these hormones 
then goes to the liver where its glycogen stores in liver are converted into glucose, thereby 
raising serum blood glucose levels. After this compensation there is a period of high blood sugar 
during fasting following an episode of hypoglycemia occurred more commonly seen during  
2am - 4 am.  
The Somogyi effect usually occurs  following an episode of untreated nighttime 
hypoglycemia
7
, thereby resulting in high blood sugar levels in the morning due to compensatory 
mechanism by counter regulatory hormones. Patients who has a high blood sugar in fasting may 
need to check their blood glucose levels during the middle of the night (for example, around          
  
3 AM). If there is a fall in blood sugar level at that time, then measures to be taken for increasing 
their food intake or lowering their insulin dose in the evening. For preventing the Somogyi effect 
The only way to avoid developing hypoglycemia in the first place. 
 
 
 Increased insulin resistance probably due to dietary fat in the supper meal 
 Late intake of supper with glucose absorbtion after bedtime. 
 
  
  
CRITERIA FOR TESTING FOR DIABETES IN ASYMPTOMATIC ADULT 
INDIVIDUALS
 
 
 
Resistance (e.g. Poly Cystic Ovarian Syndrome or Acanthosis nigricans)  
 
  
  Testing for diabetes should be considered in all individuals at age of 45 years and above, 
particularly in those with a BMI more than 25 kg/m2*, and, if normal, should be repeated  at 
3-year intervals. 
  Testing should be considered at a younger age or be carried out more frequently in 
individuals who are overweight (BMI > 25 kg/m2*) and have additional risk factors: 
         who are habitually physically inactive 
         who have a first-degree relative with diabetes 
         if persons are members of a high-risk ethnic population (e.g., African 
American, Latino, Native American, Asian American, Pacific Islander) 
         persons who have delivered a baby weighing more than 3.5 kg or who 
have been diagnosed with GDM 
         persons with history of hypertension                 
         persons with HDL cholesterol level >35 mg/dl (0.90 mmol/l) and/or a 
triglyceride level >250 mg/dl (2.82 mmol/l) 
         with history of  Poly Cystic Ovarian Syndrome 
         person who have  Impaired Glucose Tolerance  or Impaired Fasting 
Glucose 
 
         persons who have other clinical conditions associated with insulin 
  
TREAMENT 
Clear treatment goals to be set by initial assessment of the patient. These are the list of 
goal parameters to be considered during treatment.  
a. Glucose levels [fasting, before other meals, 2 hours after meals ] 
b. HbA1C 
c. Weight change 
d. Lipid levels 
e. Blood pressure levels 
LIFE STYLE ADJUSTMENT
33
 
a. Patient should get adopted to new nutrition plan 
b. Exercise activity program to be initiated (commensurate with cardiac and general 
medical status) 
MONITORING 
a. Self monitoring of blood glucose levels should be encouraged 
b. Blood pressure monitoring 
c. To monitor other metabolic parameters 
 
  
  
TAKING MEDICATION OR INSULIN FOR DIABETES 
Taking medications for other conditions
39
 : 
a. Dyslipidemia 
b. Hypertension  
c. Microalbuminuria 
d. Hypercoagulability 
e. Vascular protection 
HEALTH CARE TEAM SUPPORTS 
a. Diabetes educator 
b. Dieticians 
c. Exercise physiologist 
FREQUENT CHECKUP WITH OTHER SPECIALIST
34
 : 
a. Ophthalmologist  
b. Podiatrist  
c. Vascular specialist  
d. Mental health professionals  
e. Cardiologist  
f. Nephrologist  
 
 
 
            
 
  
ORAL ANTIDIABETIC DRUGS 
In type 2 diabetes mellitus patients when lifestyle changes are no longer sufficient for 
achieving treatment goals then antidiabetes medications are first line theraphy . The American 
diabetes association has recommended indications to start antidiabetes medications. They are  
 Treatment goals have not met even after 3 months of medical nutrition theraphy and 
exercise programs. 
 Symptomatic hyperglycemia 
 Presentation of ketosis 
 Imminent surgery 
But in most of the cases it doesn’t take 3 months to start antidiabetes drugs. American 
diabetes association made this point to say that there should be finite trial period to determine 
the effectiveness of life style. Infact the clinical trend was also to start antidiabetes  medication 
earlier in both natural history of type 2 diabetes and progressive deterioration of sugar control. 
Monotherapy , combination therapy and combine with insulin are different mode of glycemic 
control available
40
. Type 2 diabetes treatment includes aggressive e glucose control. Because 
there are more risk of microvascular and macrovascular occlusion in type 2 diabetes mellitus. As 
diabetes mellitus is more important in metabolic syndrome and  pathologically tied to it, also as 
a risk factor for cardiovascular related disorders it is important to optimize the glucose control so 
antidiabetic medications are initially tried along with lifestyle changes.
18
 
 
 
  
Table 8: 
ANTIDIABETIC 
MEDICATIONS 
DOSAGE 
 
EFFECT 
 
ADVERSE 
EFFECTS 
SULFONYLUREAS : 
FIRST GENERATION : 
Tolbutamide  
Tolazamide  
Chlorpropamide  
 
SECOND GENERATION: 
Glyburide  
Glyburide  
(micronized formulation) 
Glipizide  
Glimipride  
Gliclazide  
Gliclazide ER 
 
 
 
250 – 3000 mg 
100 – 1000 mg 
100 – 750 mg 
 
 
1.25 -20 mg 
0.75 – 12 mg 
 
2.5 – 40 mg 
1 – 8 mg 
5 – 40 mg 
5 – 20 mg 
 
 
 
Increases insulin 
secretion in 
response to rising 
glucose levels 
 
 
 
 
 
Increases insulin 
secretion response 
to hyperglycemia 
 
 
Anorexia ,Weight 
gain, nausea 
Symptomatic 
hypoglycaemia ,skin 
rahes 
 Occasionally blood 
dyscarias 
BIGUANIDES : 
 Metformin  
 
500 – 2000 mg 
 
Reduces insulin 
resistance  
Anorexia, 
abdominal 
discomfort and 
lactic acidosis . 
ALPHA-GLUCOSIDASE  
INHIBITOR : 
Acarbose  
 
Voglibose  
 
Miglitol 
 
 
25 – 150 mg if 
<60kg 
 
25 – 300 mg if 
>60 kg 
 
25 – 100 mg  
 
 
 
Slows glucose 
absorption  
 
 
Flatulence , 
abdominal bloating , 
Non response to 
carbohydrates other 
than glucose if 
hypoglycaemic  , 
(Rare) liver 
abnormalities 
 
 
  
THIAZOLIDINEDIONES  
Rosiglitazone  
Pioglitazone  
 
2 – 8 mg  
15 – 45 mg 
 
 
Reduces insulin 
resistance 
 
Increase in 
deposition of  
subcutaneous fat 
and/or fluid , 
Increases the risk of  
fractures 
in women , drop in 
haemoglobin levels  
Possible increases 
the  risk of 
myocardial 
infarction in elderly 
(rosiglitazone) , 
Increased LDL-C 
(rosiglitazone 
 
MEGLITINIDES : 
Repaglinide  
D-PHENYLALANINE : 
Netaglinide  
 
 
2 – 16 mg 
 
120 – 360 mg  
 
Stimulates the 
glucose dependent 
postprandial insulin 
release from 
functioning beta-
cells  
 
Symptomatic 
hypoglycaemia , 
Nausea, diarrhoea, 
constipation , Skin 
rashes, abnormal 
LFT ,  (Rare) 
hepatitis and/or 
jaundice 
GLP-1 AGONIST : 
Exenatide  
 
Liraglutide  
 
Maximum 10 
mcg/ dose BID 
Subcutaneously 
0.6 mg – 1.8 mg 
Subcutaneously 
 
Enhances glucose 
stimulated insulin 
secretion suppresses 
glucagon secretion, 
slows gastric 
emptying and 
reduces appetite 
 
Constitutional 
symptoms , 
Reaction at 
Injection site, 
Possible pancreatitis  
DPP-IV INHIBITORS : 
Sitagliptin  
Alogliptin  
Lingliptin  
Saxagliptin  
 
 
25 – 100 mg  
6.25 – 25 mg 
5 – 20 mg 
5 – 10 mg   
 
 
Blocks the 
degradation of GLP-
1, prolonging it’s 
action time. Effects 
are stimulation of 
insulin secretion and 
suppression of 
glucagon suppresion  
 
Upper respiratory 
tract symptoms , 
Headache , Nausea , 
occasionally 
pancreatitis 
  
SGLT2 INHIBITORS : 
Dapagliflozin  
 
2.5 – 10 mg 
 
They inhibit glucose 
reabsorbtion in 
proximal renal 
tubulesproviding a 
insulin dependent 
mechanism to 
reduce glucose 
 
INSULIN 
 Insulin is a peptide hormone which is produced by beta cells in pancreas.  
ACTIONS 
1. It regulates the metabolism of fats and carbohydrates . 
2. It promotes glucose absorption from blood to skeletal muscle and fat tissue . 
3. It inhibit the release of glucagon. 
Type 2 diabetes mellitus: 
Antidiabetes drugs are initially preffered in management of diabetes mellitus. As slowly 
beta cell declines requirement of exogenous insulin is required for  maintaining glycemic 
control. Indications for insulin are 
1) Glucose toxicity ( marked hyperglycemia leading to decreased insulin sensitivity) 
2) Decline in beta cell function and mass leading to insufficient endogenous insulin 
production 
3) Needed for effective postprandial hyperglycemia control 
4) Oral antidiabetes drugs contraindication . 
  
TREATMENT ALGORITHM FOR TYPE 2 DIABETES MELLITUS 
 
 
Reference: American diabetes association standards of medical care diabetes 2010  
 
Reinforcement of lifestyle modification  should be done at every visit, and glycosylated 
hemoglobin (HbA1c) should be checked periodically every 3 months until the HbA1c reaches 
less than 7% and  should be repeated at least every 6 months. The interventions definitely should 
be changed if the HbA1c is 7% or higher. 
  
  
GUIDE TO INSULIN THERAPHY
41
 
Patients with type 2 diabetes who are receiving exogenous insulin can often be managed 
with a singledaily dose of either intermediate or long acting insulin which also can be added to 
their oral hypoglycaemic drugs . There is no need of every time for rapidly acting insulin. 
During starting the recommended dose for basal insulin is a single dose (for example: 10 units at 
bedtime or breakfast). The basal insulin can be either  isophane or glargine. Glargine are prone 
to cause less hypoglycaemia when compared to isophane. In  long term metformin can be 
continued or added as it reduces insulin resistance and also to help reduce weight gain. 
STEP 1:  
Check that diet, physical activity and oral medication that are appropriate and also that 
complicating medical conditions are not present 
STEP 2: 
Decide the timing and type of insulin 
FASTING BLOOD 
GLUCOSE 
EVENING BLOOD 
GLUCOSE 
SCHEDULE 
High OK Night-time basal 
OK High Morning basal 
High High Twice daily isophane/once daily glargine 
 
  
  
STEP 3: 
 Decide about dose either by starting at low dose and slowly increasing the dose. 
 Single dose can be given either in morning or evening 
 Low dose may be required in thin persons, elderly and active patients. 
 High dose may be needed in over weight and underactive patients. 
STEP 4: 
 Adjustment of doses should be done in increments of 10 – 20% at intervals of 2 – 4 days  
 Mixed insulin can be used. 
SITES OF INSULIN INJECTION: 
Abdominal wall: Generally fastest and the most uniform rate of absorption. 
Legs: Slowest absorption (unless exercising). Acceptable site. 
Arms: Not recommended 
  
 
 
 
  
  
Table 9: 
INSULIN TYPE  ONSET PEAK DURATION NOTES FOR USE 
RAPIDLY ACTING 
ANALOGUE: 
 
LISPRO 
 
 
ASPART  
 
 
GLULISINE 
 
 
 
<15 minutes 
 
 
<15 minutes 
 
 
<15 minutes 
 
 
 
0.5-1.5 
hours 
 
1-3 hours 
 
 
1 hour 
 
 
 
3-5 hours 
 
 
3-5 hours 
 
 
3-5 hours 
 
 
 
 
If mixing with NPH 
rapid acting insulin 
should be drawn 
first. Mixture 
should be given 
immediately to 
avoid effect of peak 
action. 
SHORT ACTING 
PRODUCTS : 
 
REGULAR 
 
 
 
0.5-1 hours 
 
 
 
2-4 hours 
 
 
 
4-8 hours 
 
 
 
 
 
May be mixed with 
NPH in same 
syringe. Mixed 
order should be the 
clear regular to be 
drawn first and then 
cloudy NPH  
INTERMEDIATE 
ACTING PRODUCTS : 
 
NPH (NEUTRAL 
PROTAMINE 
HAGEDORN) 
 
 
 
2-4 hours 
 
 
 
4-8 hours 
 
 
 
10-18 hours 
 
 
 
 
 
 
 
LONG ACTING 
ANALOGUE : 
 
GLARGINE 
 
 
 
 
DETEMIR 
 
 
 
2-4 hours  
 
 
 
 
2-3 hours 
 
 
 
Same 
action 
throughout 
the day 
 
6-8 hours 
 
 
 
24 hours 
 
 
 
 
5.7-23.2 
hours 
 
 
 
 
Do not mix with 
any insulin. 
Available as a pen 
or vial with syringe. 
 
 
 
 
COMBINED PRODUCTS  
 
REGULAR/ NPH 30/70 
 
 
 
0.5-1 hour 
 
 
 
2-10 hours 
 
 
 
10-18 hours 
 
 
 
NPH 70% + 
REGULAR 30% . 
  
 
 
 
REGULAR/NPH 50/50 
 
 
ASPART/PROTAMINE 
30/70 
 
OR 
 
LISPRO/PROTAMINE 
25/75 
 
OR 
 
LISPRO/PROTAMINE 
50/50 
 
 
 
 
 
 
<15 minutes 
 
 
 
 
 
 
1-2 hours 
 
 
 
 
 
 
10-18 hours 
 
 
 
 
 
insulin action have 
two peaks. 
 
NPH 50% + 
REGULAR 50% 
 
ASPART 
PROTAMINE 70% 
+ ASPART 30% 
 
LISPRO 
PROTAMINE 75% 
+ LISPRO 25% 
 
LISPRO 
PROTAMINE 50% 
+ LISPRO 50% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
COMPLICATIONS OF DIABETES  
I. ACUTE:  
1. Hypoglycemia:                               
It is mostly seen in diabetic patients who are treated with insulin. The risk of 
hypoglycemia is the most important single factor as it is  limiting the attainment of  therapeutic 
goal, namely near normal glycemia
38
.  
Signs and symptoms of hypoglycemia : 
Autonomic hyperactivity: Anxiety, Palpitation, Sweating, Tremors, Hunger, Nausea and 
Hyperactivity.  
Neuroglycopaenia:  Headache , Mental dullness
38
 , Fatigue , Dizziness , Blurring of vision, 
seizure, amnesia,  confusion and unconsciousness. 
Risk factors for hypoglycemia: 
1) If there is excessive doses of insulin or insulin secretagogues. 
2)  If the exogenous glucose delivery decreased  
3) If utilization of glucose is increased  (i.e during exercise) 
4) If Endogenous glucose production is decreased ( following alcohol ingestion ) 
5) Renal failure 
6) If insulin sensitivity is decreased  
 
 
  
2. Diabetic Ketoacidosis:  
It is a major medical emergency and remains a serious cause of morbidity, principally in 
patients with type 1 diabetes. Symptoms of diabetic ketoacidosis are nausea, vomiting, excessive 
urination, thirst and abdominal pain. In severe acidosis laboured type of breathing is seen wich is 
characteristically reffered to as ―kussmaul respiration‖33                                   on physical 
examination dehydration signs are present. Due to dehydration there will be decrease in blood 
volume which causes tachycardia and hypotension. Respiratory rate is increased if kussmaul 
breathing is present.  
The cardinal biochemical features of diabetic Ketoacidosis are 
 Hyperglycaemia  
 
 Hyperketonaemia  
 
 Metabolic acidosis  
 
3) Hyperosmolar hyperglycemic state 
39
 : 
This condition is usually characterized by marked  hyperglycaemia without any 
significant hyperketonaemia or acidosis. Here Thromboembolic complications are common. It 
usually occurs in type 2 diabetes mellitus. Signs and symptoms are usually resemble like diabetic 
ketoacidosis.  
 
 
 
 
 
  
DIFFERENCE BETWEEN DIABETIC KETOACIDOSIS AND HYPEROSMOLAR  
HYPERGLYCAEMIC STATE: 
Table 10: 
 
 
 
         DKA 
 
          HHS 
plasma glucose (mg/dl) 
 
        >250           >600 
Arterial PH 
 
       <7.3           >7.3 
Sodium bicarbonate  
 
       <15           >15 
Serum or urine ketones 
  
     positive     Negative  
Effective serum osmolality 
 
    Variable          >320 
Anion gap 
  
     >12        <12 
Mental status      Variable  Stupor or coma  
Total water deficit 
  
    100      100 to 200 
Sodium (mEq/kg) 
 
    7 to 10     5 to 13 
Chloride (mEq/kg) 
 
   3 to 5     5 to 13 
Potassium (mEq/kg) 
 
    3 to 5      4 to 6 
 
Reference: associations of physician of india textbook of medicine  
  
Pseudohyponatremia is present due to osmotic effect of hyperglycemia in which water 
moves from intravascular space to extravascular space. So correct serum sodium by 
approximately 1.6 mEq/l for 100 mg/dl of glucose.  Hyperamylasemia can be seen in diabetic 
ketoacidosis and is of salivary origin.  
II. CHRONIC COMPLICATIONS 
Macrovascular Disease  
 Diabetes mellitus plays a major factor for morbidity and mortality through premature and 
accelerate atherosclerosis.  
 Coronary artery disease and cerebrovascular disease are 2 –4 times common in a diabetic 
patients and the post-infarction mortality is higher.  
 Peripheral vascular disease is a 4 – 6 times more common in diabetic patients; associated 
presence of neuropathy accentuates diabetic foot problems.  
 The usual relative protection against atherosclerosis prior to menopause is lost in diabetic 
women.  
Microvascular occlusion: 
Diabetic Neuropathy  
 It is a major cause of morbidity and premature death in diabetic patients.  
 It requires many years before becoming clinical overt.  
 
  
  
Stages:  
1. Incipient (sub clinical nephropathy)  
2. Clinical (overt nephropathy)  
3. Advanced nephropathy  
4. End stage renal disease  
Diabetic peripheral neuropathy 
34
 : 
 Diabetes is a one of the most common cause for peripheral neuropathy in India.  
 Diabetic peripheral neuropathy is most common complication in diabetes which increases 
the risk for foot ulcers and amputation. Due to significant nerve damage in their feet and 
toes, patients with diabetic peripheral neuropathy they often do not notice minor cuts, 
sores, or blisters in these areas. If these wounds were left untreated, they get infected, 
lead to gangrene, and may even require amputation of the affected area. 
CLASSIFICATION OF DIABETIC NEUROPATHY: 
 Distal symmetrical polyneuropathy 
 Autonomic polyneuropathy 
 Polyradiculopathies: 
 Diabetic amyotrophy (Diabetic lumbar polyradiculopathy) 
 Thoracic polyradiculopathy 
 Diabetic neuropathic cahexia 
 Mononeuropathy: 
 Cranial mononeuropathy 
 Peripheral mononeuropathy 
 Mononeuropathy multiplex  
  
Diabetic Retinopathy 
42
 
 Sight threatening eye disease is serious complication of diabetes and often be present 
without visual symptoms.  
 Early detection and appropriate management can greatly reduce risk of visual loss.  
 
 
  
MATERIALS AND METHODS 
Source of data  
50 patients of type 2 diabetes mellitus admitted to PSG HOSPITAL  between may 2014 
and september 2014 were included in the study
43
. Also 50 non diabetic patients admitted during 
the same period were included in the study under the control group. 
Method of collection of data 
38
:( including sampling procedures if any)  
Patients were considered to be diabetic based on WHO criteria for diagnosis of diabetes 
mellitus which is  
1. Symptoms of diabetes mellitus plus a random glucose concentration >200mg/dl 
(11.1mmol/l). The classic symptoms of diabetes mellitus include polyuria, polydypsia 
and unexplained weight loss  
OR 
2. Fasting blood glucose >126mg/dl(7.0mmol/l). Fasting is defined as no caloric intake for 
at least 8 hours.  
OR 
3. 2 hour post prandial glucose >200mg/dl. Among diabetics, the above criteria were 
considered to be included for the study. 
 
 
  
INCLUSION CRITERIA FOR CASE SELECTION: 
 Patient diagnosed to be diabetic fitting in to the above criteria. 
EXCLUSION CRITERIA FOR CASE SELECTION: 
 Associated hypertension  
 Gastrointestinal disorders 
 Impaired renal function  
 Alcoholism 
 Pancreatitis 
 Other endocrinal disorders  
 Patient using diuretics,  aminoglycosides 
 Iatrogenic administration 
INCLUSION CRITERIA FOR CONTROLS: 
 
44
Age and sex matched non diabetic patients admitted in hospital were taken as controls 
after applying the same exclusion criteria which were applied for the cases. 
ESTIMATION OF SERUM MAGNESIUM: 
Estimation of serum magnesium by chlorophosphonazo – 3  
 
 
 
  
RESULTS 
 
Study Design: 
A Comparative study consisting of 50 Diabetic Mellitus patients and 50 controls was 
undertaken to investigate the change pattern of serum magnesium in DM cases when compared 
to controls
29
 
Table-11:  
Age distribution 
Age 
Gender  
Male Female Total 
<40 3 4 7 
41-50 15 12 27 
51-60 14 11 25 
61-70 12 9 21 
>70 15 5 20 
Total 59 41 100 
 
Table 12 
Sex distribution 
Gender 
Group 
Cases Controls Total 
Male 23 36 59 
Female 27 14 41 
Total 50 50 100 
  
Mean Clinical Variables 
  
 
 
Age 
  
  
Mean SD 
95% CI for Mean 
Minimum Maximum 
„P‟ 
value 
Lower 
Bound 
Upper 
Bound 
Male 59 13 56 62 27 82 
 Female 55 12 52 59 32 80 >0.05 
Overall 58 12 55 60 27 82  
 
The mean age of patients (both control and cases ) included in the study was 58 he 
mean age For male include in this study was 59 and in female was 55 There was no 
significant difference in the outcome among different age groups and gender (p value > 0.05). 
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Table 13: 
Comparison of serum magnesium levels between cases and controls: 
Magnesium 
Group  
Cases Controls Total 
<1 1 0 1 
1.1-1.5 30 8 38 
1.6-2.0 19 40 59 
>2.1 0 2 2 
Total 50 50 100 
 
 
Mean Sr. Magnesium in study Groups 
Clinical Variables 
Mean SD 
95% CI for 
Mean 
Minimum Maximum 
„P‟ 
value 
Lower 
Bound 
Upper 
Bound 
 
MAGNESIUM 
Cases 
1.47 0.20 1.4 1.5 1.0 1.8 
 Controls 
1.71 0.20 1.7 1.8 1.2 2.1 
<0.001 
Total 
1.59 0.23 1.5 1.6 1.0 2.1 
 
 
There is significant difference between levels of serum magnesium levels among 
diabetics and controls. The mean serum magnesium levels in cases and controls are 1.47 
mg/dl and 1.71 mg/dl respectively 
45
. Cases are 24 times more likely to have less 
serum magnesium (<1.50mg/dl) when compared to controls with p<0.001
46
.  
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Table 14  
Effect of type of treatment on Serum magnesium 
Mode of Treatment Cases (%) 
INSULIN 
21 42% 
OHA 
29 58% 
Total 50 100% 
 
 
Mean Sr.Magnesium with Treatment Group 
MAGNESIUM 
  
Mean SD 
95% CI for 
Mean 
Minimum Maximum 
„p‟ 
value 
Lower 
Bound 
Upper 
Bound 
INSULIN 
1.44 0.2 1.3 1.5 1.0 1.8 
 OHA 
1.49 0.2 1.4 1.6 1.1 1.8 >0.05 
Total 
1.47 0.2 1.4 1.5 1.0 1.8 
  
The mean value for diabetic patients receiving insulin therapy was 1.44 ± 0.2 and in 
patients who are receiving OHA was 1.49 ± 0.2. There was no significant difference in the 
outcome among treatment  groups (p value > 0.05) . 
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Table 15: 
Effect of serum magnesium in Diabetic Retinopathy: 
DM Retinopathy Cases (%) 
Present 
19 38% 
Absent 
31 62% 
Total 50 100% 
 
Mean Sr. Magnesium with DM Retinopathy 
  
MAGNESIUM 
 Mean SD 
95% CI for 
Mean 
Minimum Maximum 
„p‟ 
value 
Lower 
Bound 
Upper 
Bound 
Present 
1.45 0.19 1.4 1.5 1.20 1.80 
 Absent 
1.48 0.21 1.4 1.6 1.00 1.80 >0.05 
Total 
1.47 0.20 1.4 1.5 1.00 1.80 
  
The mean value for patients with diabetic retinopathy was 1.45  0.19 and in patients 
without diabetic retinopathy was 1.48 0.21. There was no significant difference in the outcome 
among treatment  groups (p value > 0.05) . 
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Table 16: 
Effect of level of Control of Diabetes Mellitus on Serum magnesium
47
 
DM CONTROLLED/ UNCONTROLLED in the study Group 
Controlled/Uncontrolled Cases (%) 
Controlled 19 16% 
Uncontrolled 31 26% 
Total 50 43% 
 
Mean Sr.Magnesium with DM Out come  
  
 MAGNESIUM 
Mean SD 
95% CI for 
Mean 
Minimum Maximum 
„p‟ 
value 
Lower 
Bound 
Upper 
Bound 
Controlled 1.57 0.19 1.476 1.661 1.20 1.80 
<0.01 
Uncontrolled 1.41 0.19 1.34 1.479 1.00 1.70 
Total 1.47 0.20 1.412 1.528 1.00 1.80 
 
There was significant difference between magnesium levels among controlled and 
uncontrolled diabetics. The mean serum magnesium levels among controlled and uncontrolled 
diabetics were 1.57 mg/dl and 1.41 mg/dl respectively
48
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Table 17 
Effect of serum magnesium on creatinine, FBS, PPBS and Age 
Mean of Clinical Variables 
  
Clinical Variables 
Mean SD 
95% CI for 
Mean 
Minimum Maximum 
„p‟ 
value 
Lower 
Bound 
Upper 
Bound 
AGE Cases 57.16 11.5 53.9 60.4 27 82 
 Controls 57.96 13.3 54.2 61.7 38 82 >0.05 
Total 57.56 12.4 55.1 60.0 27 82  
CREATININE Cases 0.828 0.3 0.8 0.9 0.4 1.2 
 Controls 0.778 0.2 0.7 0.8 0.2 1.2 >0.05 
Total 0.803 0.2 0.8 0.9 0.2 1.2  
FBS Cases 188.74 92.9 162.3 215.1 69 485 
 Controls 102.32 7.5 100.2 104.5 85 119 <0.001 
Total 145.53 78.6 129.9 161.1 69 485  
PPBS Cases 231.72 91.3 205.8 257.7 114 485 
 Controls 123.66 11.0 120.5 126.8 91 140 <0.001 
Total 177.69 84.5 160.9 194.5 91 485  
 
There is a significant difference between magnesium levels among fasting and 
postprandial blood glucose levels
49
. The mean value for fasting blood glucose among cases was 
188.74and in controls was 102.32. The mean value for fasting blood glucose among cases was 
231.72 and in controls were 123.66.  
There was no significant difference between magnesium levels and creatinine in this 
study. The mean value for creatinine in cases was 0.828 ± 0.3 and in controls was 0.778 ± 0.2 
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 Table 18: 
Age Group with Magnesium level in the study Group 
Group AGE Mean SD N 
Cases 
<40 1.55 0.07 2 
41-50 1.41 0.22 12 
51-60 1.47 0.21 16 
61-70 1.47 0.21 14 
>70 1.57 0.20 6 
Total 1.47 0.20 50 
Control 
<40 1.74 0.19 5 
41-50 1.83 0.19 15 
51-60 1.60 0.26 9 
61-70 1.73 0.05 7 
>70 1.64 0.16 14 
Total 1.71 0.20 50 
Overall 
<40 1.69 0.19 7 
41-50 1.64 0.29 27 
51-60 1.52 0.23 25 
61-70 1.56 0.21 21 
>70 1.62 0.17 20 
Total 1.59 0.23 100 
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Table 19: 
Causes in study Group 
  
Causes 
Group  
Total Cases Controls 
UTI 8 7 15 
URTI 0 4 4 
LRTI 5 5 10 
FOLLOW UP 14 0 14 
MYALGIA 0 9 9 
VIRAL FEVER 1 9 10 
GERD 0 5 5 
OA KNEE 4 1 5 
AGE 4 1 5 
APD 0 3 3 
PUO 3 0 3 
MIGRAINE 3 0 3 
GASTRITIS 2 0 2 
CELLULITIS 1 1 2 
PERIPHERAL NEUROPATHY 2 0 2 
SINUSITIS 0 2 2 
OTHERS 3 3 6 
Total 50 50 100 
 
  
  
Infections were the most common cause for admission in both diabetes and non diabetic 
patients  (UTI 15% , URTI 4%, LRTI 10%, AGE 5%, CELLULITIS 2%, SINUSITIS 2% PUO 
3% and VIRAL FEVER 10%)
50
 . 
The next most cause for admission is uncontrolled diabetes who came for regular follow 
up in diabetic individuals . other cause are fibromyalgia in control patients accounting for 9 % of 
admission ansd osteoarthritis of knee accounts for 5% of admission in both cases and controls. 
Gastroesophageal reflux disease account for 5% of admission in controls. Acid peptic disease 
other than GERD account for 3% of admission in controls. Migraine accounts for 3 % of 
admission in  cases. Peripheral neuropathy account for 2 % of admission in cases. Other causes 
for admission are 6% in both cases and controls. 
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Table 20: 
Mean Clinical Variables with Treatment Group 
  
  
  
  
Mean SD 
95% CI for 
Mean 
Minimum Maximum 
„p‟ 
value 
Lower 
Bound 
Upper 
Bound 
CREATININE 
INSULIN 0.8 0.3 0.7 0.9 0.4 1.2 
>0.05 OHA 0.8 0.3 0.7 0.9 0.5 1.2 
Total 0.8 0.3 0.8 0.9 0.4 1.2 
FBS 
INSULIN 215.7 88.5 175.4 256.0 100 423 
>0.05 OHA 169.2 92.5 134.0 204.4 69 485 
Total 188.7 92.9 162.3 215.1 69 485 
HbA1C 
INSULIN 8.5 1.6 7.7 9.2 5.9 12.3 
<0.05 OHA 7.5 1.2 7.1 8.0 6.1 9.5 
Total 7.9 1.5 7.5 8.3 5.9 12.3 
PPBS 
INSULIN 258.5 92.0 216.7 300.4 135 485 
>0.05 OHA 212.3 87.3 179.1 245.5 114 415 
Total 231.7 91.3 205.8 257.7 114 485 
 
There are no any significant difference between treatment group with relation to 
creatinine, fasting and post prandial blood sugar. Whereas there is a significant difference 
between treatment group and glycosylated hemoglobin level. The mean value for diabetic 
patients receiving insulin and  OHA was 8.5 and 7.5 respectively. 
 
 
  
Table 21: 
Mean Clinical Variables with DM Retinopathy 
  
  
  
  
Mean SD 
95% CI for 
Mean 
Minimu
m 
Maximu
m 
„p‟ 
value 
Lower 
Bound 
Upper 
Bound 
CREATININE 
Present 
0.8 0.3 0.7 0.9 
0 
.4 1.2 
>0.05 
Absent 0.8 0.3 0.7 0.9 0.4 1.2 
Total 0.8 0.3 0.8 0.9 0.4 1.2 
FBS 
Present 221.3 113.8 166.4 276.1 69 485 
<0.05 Absent 168.8 72.4 142.2 195.4 96 359 
Total 188.7 92.9 162.3 215.1 69 485 
HbA1C 
Present 8.1 1.4 7.5 8.8 5.9 11.2 
>0.05 Absent 7.8 1.5 7.2 8.4 6.1 12.3 
Total 7.9 1.5 7.5 8.3 5.9 12.3 
PPBS 
Present 253.3 82.8 213.4 293.2 142 389 
>0.05 Absent 218.5 95.1 183.6 253.4 114 485 
Total 231.7 91.3 205.8 257.7 114 485 
 
There are no significant difference between diabetic retinopathy and glycosylated 
hemoglobin, post prandial sugar and creatinine. There is a significant difference between fasting 
blood sugar and diabetic retinopathy. The mean value for patient with diabetic retinopathy with 
fasting blood sugar is 221.3 and with out diabetic retinopathy the mean value for fasting blood 
sugar is 168.8.  
  
  
Table 22: 
Mean Clinical Variables with DM Out come 
  
  
  
  
Mean SD 
95% CI for 
Mean 
Minimum Maximum 
„p‟ 
value 
Lower 
Bound 
Upper 
Bound 
MAGNESIUM 
Controlled 1.568 0.1916 1.476 1.661 1.2 1.8 
 
<0.01 
 
Uncontrolled 1.41 0.1886 1.34 1.479 1 1.7 
Total 1.47 0.2033 1.412 1.528 1 1.8 
CREATININE 
Controlled 0.864 0.2726 0.732 0.995 0.5 1.2 
 
>0.05 
 
Uncontrolled 0.806 0.2452 0.716 0.896 0.4 1.2 
Total 0.828 0.2548 0.755 0.9 0.4 1.2 
FBS 
Controlled 108.05 7.397 104.49 111.62 96 121 
 
<0.001 
 
Uncontrolled 238.19 86.063 206.63 269.76 69 485 
Total 188.74 92.88 162.34 215.14 69 485 
HbA1C 
Controlled 6.447 0.2796 6.313 6.582 5.9 6.9 
<0.001 Uncontrolled 8.832 1.1053 8.427 9.238 7.3 12.3 
Total 7.926 1.4642 7.51 8.342 5.9 12.3 
PPBS 
Controlled 147.26 16.713 139.21 155.32 114 170 
 
<0.001 
 
Uncontrolled 283.48 78.583 254.66 312.31 165 485 
Total 231.72 91.348 205.76 257.68 114 485 
 
There is a significant difference between relationship of diabetes outcome with serum 
magnesium level, FBS, glycosylated hemoglobin and PPBS. The mean value for magnesium in 
controlled patient was 1.568 and uncontrolled was 1.41. The mean value for fasting blood sugar 
level in controlled patient was 108.05 and uncontrolled was 238.19. The mean value for 
glycosylated hemoglobin  in controlled patient was 6.447 and uncontrolled was 8.832. The mean 
value for postprandial sugar in controlled patient was 147.26 and uncontrolled was 283.48.  
  
DATA SUMMARY 
  
„P‟ value 
GENDER   
 
  
Male 59% 
 
  
Female 41% 
 
  
MEAN AGE 
  
  
Male 59+/-13 
 
>0.05 
Female 55+/-12 
  Overall 58+/-12 
  AGE Cases Controls 
 <40 2% 5% 
 41-50 12% 15% 
 51-60 16% 9% >0.05 
61-70 14% 7% 
 >70 6% 14% 
 GENDER 
   Male 23% 36% <0.05 
Female 27% 14% 
 MAGNESIUM 
   <1-1 1% 0% 
 1.1-1.5-2 30% 8% >0.05 
1.6-2.0-3 19% 40% 
 2.1-4 0% 2% 
 TREATMENT 
   INSULIN 42% 
  OHA 58% 
  RETINOPATHY 
   Present 38% 
  Absent 62% 
  Controlled 38% 
  Uncontrolled 62% 
  
  
CAUSES 
   UTI 8% 7% 
 URTI 0% 4% 
 LRTI 5% 5% 
 FOL UP 14% 0% 
 MYALGIA 0% 9% <0.05 
V FEVER 1% 9% 
 GERD 0% 5% 
 OA KNEE 4% 1% 
 AGE 4% 1% 
 APD 0% 3% 
 PUO 3% 0% 
 MIG 3% 0% 
 GASTRITIS 2% 0% 
 CELLULITIS 1% 1% 
 PNEURO 2% 0% 
 SINUSITIS 0% 2% 
 OTHERS 3% 3% 
 GROUP 
  
  Cases 1.47 0.20 
 Controls 1.71 0.20 <0.01 
TREATMENT 
  
  INSULIN 1.44 0.2 >0.05 
OHA 1.49 0.2 
 Present 1.45 0.19 >0.05 
Absent 1.48 0.21 
 Controlled 1.57 0.19 <0.01 
Uncontrolled 
1.41 0.19   
AGE   
 
  
  
Cases 57.16 11.5 >0.05 
Controls 57.96 13.3   
CREATININE   
 
  
Cases 0.828 0.3   
Controls 0.778 0.2 >0.05 
FBS   
 
  
Cases 188.74 92.9   
Controls 102.32 7.5 <0.05 
PPBS   
 
  
Cases 231.72 91.3 <0.05 
Controls 123.66 11.0   
 
STATISTICAL ANALYSIS: 
The data are reported as the mean +/- SD or the median, depending on their distribution. 
The differences in quantitative variables between groups were assessed by means of the  
unpaired t test. Comparsion between groups was made by the Non parameteric Mann - 
whitney test 
ANOVA was used to assess the quantative variables. 
The chi square test was used  assess differences in categoric variables between groups. 
Multivariate analysisis was performed. 
A p value of <0.05 using a two-tailed test was taken as being 
of significance for all statistical tests. All data were analysed with a statistical software  
 
                                
                                                
 
 
 
 
  
DISCUSSION 
The magnesium deficiency always  been associated with underlying chronic diseases, 
amongst them, diabetes mellitus is the most common
51
 . There are epidemiological studies which 
have shown that low levels of magnesium intake in the general population is aways associated 
between the ingestion of food rich in magnesium and the reduction of diabetes its complications. 
Hypomagnesemia is nowadays  frequently present in diabetic patients, however there is not an 
exact  mechanism for reason for  magnesium deficiency in diabetes mellitus
52
.  
The present study included 50 type 2 diabetic patients and 50 control subjects. Serum magnesium 
levels were determined in all these subjects.  
Table 23a C.S. Yajnik et al 
Age 
Characteristics 
Non diabetics 
(controls) 
Insulin treated 
Diabetics 
Non insulin 
treated 
diabetics 
All diabetics 
C.S.Yajnik et al  46.5(n=30) 45.9(n=32) 59.7(n=55) 54.7(n=87) 
Present study  57.96(n=50) 53.57(n=21) 59.75(n=29) 57.16(n=50) 
 
The present study had diabetic patients ranging from 27-82 years. The average age of controls in 
the present study was 57.96 years while in the study of C.S.Yajnik et al was 46.5 years. The 
mean age of diabetics in the present study was 57.16 years as against 54.7 in study of C.S.Yajnik 
et al.,
 
The mean age of patients on insulin was 53.75 years and 45.9 years in the present and the 
study conducted by C.S.Yajnik et al respectively and the mean age of non insulin treated 
diabetics was 59.75 years and 59.7 years respectively in the present study and the study of 
C.S.Yajnik et al. 
  
Table 23b C.S. Yajnik et al 
Men (%) Non diabetics 
(controls) 
Insulin treated 
diabetics 
Non insulin 
treated 
diabetics 
All diabetics 
C.S.Yajnik et al  56% 59% 76% 70% 
Present study  72% 43% 52% 46% 
 
The percentage of patients in the insulin treated diabetic group who were men was 43% 
in  the present study and the study done by C.S. Yajnik et al was 59%. The percentage of men in 
the non insulin treated diabetic group was 52% and 76% in the present study and the study 
conducted by C.S. Yajnik et al respectively. 
A.P.Jain, N.N.Gupta and Abhay Kumar (1976)
 
 
Table 24a -Serum magnesium in controls and diabetics 
  
A.P.Jain, N.N.Gupta and Abhay Kumar (1976) selected 85 cases, which included 20 comparable 
healthy adults and 65 diabetics of whom 50 diabetics were without apparent renal involvement. 
They have studied simultaneously the intracellular (erythrocytic), extracellular (serum) and 
urinary magnesium levels in controls and diabetics. An attempt to compare the findings in these 
groups and in controlled and uncontrolled diabetics: those getting insulin with the group not 
getting insulin was made In the diabetic group low serum, normal erythrocyte and high urinary 
magnesium levels were recorded in comparison to controls (1.71 ± 0.20 v/s 2.07±0.25 in 
controls and 1.47 ± 0.20 v/s 1.67 ± 0.37 in diabetics). 
 Controls Diabetics 
A.P.Jain, N.N.Gupta 
and Abhay Kumar  
2.07 ± 0.25 1.67 ± 0.37 
Present study 
 
1.71 ± 0.20 1.47 ± 0.20 
  
Table 24b 
Serum magnesium in controlled and uncontrolled diabetics 
 Controlled Uncontrolled 
A.P.Jain, N.N.Gupta and 
Abhay Kumar  
1.85±0.08 1.68±0.12 
Present study  1.57 ± 0.19 1.41 ± 0.19 
 
On establishing the relationship between magnesium levels and the state of control of diabetes, it 
was observed that in poorly controlled diabetes patient’s serum and urinary magnesium levels 
were respectively lower and higher than that of poorly controlled (1.57 ± 0.19 v/s 1.85 ± 0.08 in 
fairly controlled and 1.41 ± 0.19 v/s 1.68 ± 0.12 in poorly controlled) with no significant 
difference in erythrocytic magnesium levels. 
Table 25a 
Serum magnesium in insulin treated and OHA treated diabetics 
 Insulin OHA’S 
A.P.Jain, N.N.Gupta and Abhay 
Kumar  
1.59 ± 0.13 1.90 ± 0.18 
Present study  1.44 ± 0.20 1.49 ± 0.20 
The diabetics getting insulin therapy had lower serum and higher urinary magnesium levels than 
those getting OHA’S (1.44 ± 0.20 v/s 1.59±0.13 in the insulin treated and 1.49 ± 0.20 v/s 1.90 ± 
0.18 in the OHA treated subjects). The present study compared similar parameters that  
was done by A.P.Jain, N.N.Gupta and Abhay Kumar and found variations similar to that study. 
 
  
Nadler JL (1992) 
Table 25b - Serum magnesium in diabetics and controls 
 Controls Diabetics 
Nadler JL  2.31 ± 0.12 1.94 ± 0.05 
Present study  1.71 ± 0.20 1.47 ± 0.20 
 
Nadler JL, Malayan S, Luong H, Shaw S, Natrajan RD and Rude RK (1992) evaluated 
intracellular (erythrocytic) Mg
2+ 
concentration in 20 type 2 diabetics. In addition, effects of  
intravenous 3-h drip or 8 weeks of oral magnesium supplementation on intracellular Mg
2+ 
concentration levels and platelet reactivity was studied.  
The results showed intracellular Mg
2+ 
concentration of diabetic patients was significantly 
reduced compared with values in non diabetic control subjects. Serum magnesium levels were 
also reduced in the diabetic patients compared control subjects (1.71 ± 0.20 v/s 2.31 ± 0.12 in 
controls and 1.47 ± 0.20 v/s 1.94 ± 0.05 in diabetics). Oral magnesium supplementation for 8 
weeks (400mg/day) restored RBC magnesium concentration to normal without significantly 
changing serum magnesium concentration. Both intravenous and oral magnesium 
supplementation markedly reduced platelet reactivity in response to the thromboxane A2 analog, 
U46619. 
The present study correlated with the study done by Nadler JL, Malayan S, Luong H, 
Shaw S, Natrajan RD and Rude RK with respect to the comparison of serum magnesium in 
diabetics and controls. However the present study did not include evaluating the effects of oral or 
IV magnesium supplementation 
  
Nagase N (1996) 
Table 26 : 
Serum magnesium in diabetics and controls 
 Controls Diabetics 
Nagase N  2.30 ± 0.32  1.90 ± 0.37  
Present study  1.71 ± 0.20  1.47 ± 0.20 
 
Nagase N (1996) studied the interrelationships between hypertension, ischemic heart 
disease and diabetes mellitus and diabetes mellitus in the diabetic subjects without ischemic 
heart disease or with ischemic heart disease and subjects with ischemic heart disease which were 
not complicated with diabetes mellitus.  
Their results showed serum magnesium levels of diabetes mellitus (1.90±0.37) was 
significantly lower than that of normal controls (2.30±0.32). They also concluded that serum 
magnesium level of poorly controlled diabetic patients is lower than that of well controlled 
diabetic patients. These results suggested that magnesium deficient state is one of the causes of 
insulin resistance. The present study did not evaluate the interrelations between hypertension, 
ischemic heart disease.  
However the magnesium levels of diabetics as compared to controls and the Comparison 
of serum magnesium levels between well controlled and poorly controlled diabetics had a 
positive correlation with the present study.  
Garland H O in his study speculated on a potential link between magnesium deficit of 
diabetes and several diabetic complications including cardiovascular problems and retinopathy. 
  
Rude R K suggested repletion of the deficiency or prophylactic supplementation with oral 
magnesium may help avoid or ameliorate such complications as arrhythmias, hypertension and 
sudden cardiac death and may improve the course of diabetic condition.  
  
  
LIMITATIONS OF THE STUDY 
However in the present study, the complications of diabetes in relation to 
hypomagnesemia were not studied. Also magnesium supplementation and its effects towards 
magnesium levels or metabolic control was not done in this study which can be taken as 
limitations of the present study.  
 There was no scope for follow up in the present study. Hence change in magnesium states 
with respect to improvement or worsening of diabetic state in the long run was not studied.  
This study focuses on estimating magnesium levels in type 2 diabetics at a given point 
(during admission) but not on therapeutically correcting hypomagnesemia or otherwise (not 
correcting) in the future course of the disease and its outcome.  
 
 
 
 
 
 
 
 
 
  
  
CONCLUSION 
1. Serum magnesium levels were lower in type 2 diabetic patients when compared to 
controls.  
2. Levels of serum magnesium in uncontrolled type 2 diabetic patients were further lower 
than those in whom diabetes was under control.  
3. Hypomagnesemia is a factor in type 2 diabetes mellitus patients leading to various 
complications. Hence it is worthwhile estimating magnesium levels in type 2 diabetes 
mellitus patients and probably correlates their relationship with various complications.  
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ANNEXURES 
PROFORMA 
TITLE:  
SERUM MAGNESIUM AS AN EFFECTIVE TOOL IN MONITORING THE 
CONTROL OF TYPE II DIABETES MELLITUS 
PARTICULARS OF THE PATIENT:  
Name: IP NO:  
 
Age : Ward No:  
 
Sex : Hospital: RLJH/SNRH  
 
Religion: DOA:  
 
Address: DOD:  
 
Occupation: Marital Status  
 
Education:  
 
CHIEF COMPLAINTS:  
 
Polyuria  
 
Polydypsia  
 
Blurring of vision  
  
Weight loss  
 
Tiredness  
 
Polyphagia  
 
Pruritus  
 
Aches and pains  
 
Skin complaints 
HISTORY OF PRESENT ILLNESS:  
 
CARDIOVASCULAR SYMPTOMS:  
 
Angina  
 
Exertional dyspnea  
 
Orthopnea  
 
Paroxysmal nocturnal dyspnea  
 
Palpitations  
 
Syncope  
 
  
Sweating  
 
Swelling of feet  
 
PERIPHERAL VASCULAR SYMPTOMS  
 
Intermittent claudication  
 
Gangrene  
 
Impotence  
 
Thrombophlebitis  
 
NEUROLOGICAL SYMPTOMS  
 
Giddiness  
 
Headache  
 
Vomiting  
 
Transient ischemic attacks  
 
Loss of consciousness  
 
Stroke  
VISUAL SYMPTOMS  
  
Blurring of vision  
 
Progressive loss of vision  
 
Sudden blindness  
 
RENAL SYMPTOMS  
 
Symptoms of urinary tract infection:  
 
Dysuria  
 
Fever with chills  
 
Flank pains  
 
Symptoms of nephropathy:  
 
Puffiness of face  
 
Nocturnal pains  
 
Sensory ataxia  
 
Trophic ulcers  
  
  
SYMPTOMS OF NEUROLOGICAL COMPLICATIONS  
 
Symptoms of polyneuropathy:  
 
Tingling and numbness  
 
Nocturnal pains  
 
Sensory ataxia  
 
Trophic ulcers  
 
Charcot’s joints  
 
Symptoms of mononeuropathy:  
 
Wrist drop 
Foot drop  
 
Symptoms of cranial nerve involvement  
 
Diplopia  
 
Squint  
 
Deviation of angle of mouth  
 
  
Inability to close the eyes  
 
Symptoms of radiculopathy  
 
Symptoms of autonomic neuropathy  
 
Dysphagia  
 
Vomiting  
 
Diarrhea  
 
Syncope  
 
Symptoms of amyotrophy  
 
Parasthesiae of anterior thigh  
 
Thinning of proximal muscles  
 
Weakness of proximal muscles  
 
Symptoms of diabetic skin complications  
 
  
  
DIABETES HISTORY  
 
Diabetes diagnosed in the year  
Duration of diabetes  
 
Diabetic family history  
 
Diabetic Ketoacidosis  
 
Drugs used for diabetes 
PAST HISTORY:  
 
PERSONAL HISTORY:  
 
Habits  
 
Diet  
 
Appetite  
 
Bowel and bladder habits  
 
FAMILY HISTORY:  
 
Diabetes  
 
Hypertension/ischemic heart disease/CVA/obesity/sudden death  
  
OBSTETRICS AND GYNECOLOGICAL HISTORY:  
Menarche Menopause  
 
Gravida Para  
 
Abortions  
 
History of still births  
 
History of delivery of large babies  
 
GENERAL PHYSICAL EXAMINATION  
 
Built: well/moderate/poor  
 
Anemia/cyanosis/clubbing/koilonychias/pedal edema/lyphadenopathy/icterus  
 
Pulse  
 
Jugular venous pressure  
 
Blood pressure  
 
Peripheral pulses  
 
Skin changes 
 
  
Eyes: Normal/Xanthoma/Arcus/Cataract  
Fundus  
 
SYSTEMIC EXAMINATION  
 
CARDIOVASCULAR SYSTEM  
 
Inspection  
 
Palpation  
 
Percussion  
 
Auscultation  
 
RESPIRATORY SYSTEM  
 
Inspection  
 
Palpation  
 
Percussion  
 
Auscultation  
 
  
  
EXAMINATION OF ABDOMEN  
 
Inspection  
Palpation  
 
Percussion  
 
Auscultation  
EXAMINATION OF CENTRAL NERVOUS SYSTEM  
 
Higher mental functions  
 
Cranial nerves  
 
Motor system 
Tone  
 
Power  
 
Reflexes  
 
Coordination  
 
Involuntary movements  
 
Sensory system  
 
  
Touch  
 
Pain  
 
Temperature  
 
Vibration  
 
Position  
 
Cortical sensation  
 
INVESTIGATIONS  
 
Urine: Albumin  
 
Sugar  
 
Microscopy  
 
Ketone bodies  
 
Total count  
 
Differential count  
 
Erythrocyte sedimentation rate  
  
Fasting blood sugar  
 
Serum magnesium  
 
Blood urea 
Serum creatinine  
 
Chest X-ray  
 
ECG  
 
USG abdomen  
 
DIAGNOSIS  
 
TREATMENT GIVEN  
 
Oral hypoglycemic agents  
 
Insulin  
 
Oral hypoglycemic agents + Insulin  
 
                                                                                                                  Signature of the candidate  
 
Signature of guide                                                                                          Signature of co-guide 
  
KEY TO MASTER CHART  
 
1. FBS- Fasting blood sugar  
 
2. Mg- Serum magnesium  
 
3. SC- Serum creatinine  
 
4. RET- Retinopathy  
 
5. C- Controlled  
 
6. UC-Uncontrolled  
 
7. T- Treatment  
 
8. CFA-Cause for admission  
 
9. NA-Not applicable  
 
10. URTI- Upper respiratory tract infection  
 
11. LRTI- Lower respiratory tract infection  
 
12. MEN- Meningitis  
 
13. MAL-Malaria  
  
14. CVA- Cerebrovascular accident  
 
15. IHD- Ischemic heart disease.  
 
16. PTB- Pulmonary tuberculosis  
 
17. APD- Acid peptic disease  
 
18. AC- Acute cholecystitis  
 
19. UTI-Urinary tract infection’  
 
20. I- Insulin  
 
21. OHA- Oral hypoglycemic agents  
 
              
          
 
 
 
 
 
 
  
  
CASES:  
 
  
S.NO AGE SEX OP/IP MAGNESIUM CREATININE TREATMENT DM RETINOPATHY CONTROLLED/ UNCON CAUSE FBS HbA1C PPBS
1 46 M I14017670 1.1 0.72 INSULIN NIL UNCONTROLLED CELLULITIS 256 8.2 362
2 82 M I14017636 1.3 1 OHA PRESENT CONTROLLED LRTI 114 6.5 165
3 65 F I14017717 1.3 0.76 INSULIN PRESENT UNCONTROLLED GASTRITIS 241 7.3 245
4 52 F I14017807 1.7 0.69 INSULIN NIL UNCONTROLLED VIRAL FEVER 214 9.2 289
5 72 F I14017528 1.5 0.6 OHA NIL CONTROLLED UTI 120 6.3 156
6 80 F I14017907 1.7 0.52 OHA NIL CONTROLLED BA 102 6.7 169
7 32 F I14018015 1.5 0.96 INSULIN PRESENT UNCONTROLLED PUO 156 8.3 365
8 72 M I14017806 1.7 0.45 INSULIN PRESENT UNCONTROLLED HEADACHE 289 11.2 358
9 52 F O14033635 1.6 0.57 OHA NIL UNCONTROLLED FOLLOW UP 165 8 254
10 45 F O14039203 1.3 1.2 OHA NIL CONTROLLED FOLLOW UP 96 6.1 160
11 56 M O14035409 1.4 1 OHA PRESENT UNCONTROLLED FOLLOW UP 198 8.5 369
12 52 M O14030602 1.3 0.5 OHA PRESENT UNCONTROLLED FOLLOW UP 69 9.1 298
13 53 M O12064062 1.2 0.6 INSULIN PRESENT CONTROLLED FOLLOW UP 115 6.8 145
14 65 M O13056574 1.2 0.9 INSULIN NIL UNCONTROLLED FOLLOW UP 359 9.1 214
15 56 M O13082690 1.7 1.2 INSULIN NIL CONTROLLED FOLLOW UP 102 6.9 170
16 45 M O12017429 1.5 1 OHA NIL CONTROLLED FOLLOW UP 110 6.5 156
17 58 F O13056307 1.6 0.5 OHA PRESENT UNCONTROLLED FOLLOW UP 485 8.6 245
18 27 M I14018500 1 INSULIN PRESENT UNCONTROLLED UTI 321 8.4 312
19 50 M I14018567 1.3 1.1 OHA PRESENT UNCONTROLLED AGE 254 8.2 389
20 65 F I14018397 1.1 1.2 OHA NIL UNCONTROLLED UTI 214 8.6 415
21 50 F I14017656 1.5 1.1 INSULIN NIL UNCONTROLLED PUO 210 7.5 225
22 50 M I14018794 1.8 1.2 OHA NIL CONTROLLED OA KNEE 110 6.6 138
23 65 M I14018765 1.4 0.5 OHA NIL UNCONTROLLED UTI 165 9.5 365
24 62 F I14019320 1.4 0.65 OHA PRESENT UNCONTROLLED LRTI 303 9.5 225
25 65 F I14019215 1.4 0.8 OHA NIL CONTROLLED UTI 120 6.1 138
26 56 F I14019198 1.6 0.5 OHA NIL CONTROLLED LRTI 102 6.2 140
27 74 M I14018722 1.4 0.89 OHA NIL UNCONTROLLED OA KNEE 105 9.2 201
28 55 F I14019233 1.2 1.2 INSULIN PRESENT UNCONTROLLED PERIPHERAL NEUROPATHY 198 9.5 298
29 52 F I14019013 1.5 0.42 INSULIN NIL UNCONTROLLED PERIPHERAL NEUROPATHY 231 8.8 319
30 70 F I14019104 1.7 0.75 INSULIN NIL UNCONTROLLED LRTI 186 7.8 347
31 56 F I14019513 1.5 0.67 OHA NIL UNCONTROLLED AGE 250 8.6 223
32 66 M I14019423 1.5 0.93 OHA PRESENT UNCONTROLLED MIGRAINE 230 9.3 316
33 51 M I14019495 1.6 1.08 INSULIN NIL UNCONTROLLED AGE 198 12.3 485
34 73 M I14019323 1.8 1.02 OHA NIL CONTROLLED BPPV 121 6.5 124
35 54 M O14039633 1.7 0.68 OHA PRESENT CONTROLLED FOLLOW UP 103 6.6 168
36 45 F O13035362 1.3 0.84 INSULIN NIL UNCONTROLLED FOLLOW UP 200 10.5 225
37 65 M O12071843 1.6 1.2 INSULIN NIL CONTROLLED FOLLOW UP 100 6.7 158
38 46 F O14046252 1.6 0.49 OHA NIL UNCONTROLLED FOLLOW UP 201 7.5 165
39 65 M O12010803 1.6 1.07 OHA NIL CONTROLLED FOLLOW UP 103 6.4 114
40 65 M I14019879 1.8 1.2 OHA NIL CONTROLLED LRTI 106 6.5 125
41 66 F I14019764 1.8 0.54 INSULIN PRESENT CONTROLLED UTI 105 5.9 160
42 49 F I14020107 1.2 0.49 INSULIN PRESENT UNCONTROLLED OA KNEE 423 9.6 225
43 69 F I14020150 1.4 0.57 OHA NIL CONTROLLED OA KNEE 114 6.1 135
44 56 F I14019800 1 0.81 INSULIN NIL UNCONTROLLED UTI 218 9.5 191
45 56 F I14020025 1.5 0.67 OHA NIL UNCONTROLLED UTI 198 8.6 221
46 41 F I14019629 1.7 0.87 OHA PRESENT CONTROLLED PUO 106 6.3 142
47 45 M I14020484 1.2 0.92 OHA NIL UNCONTROLLED AGE 353 8.5 254
48 56 F I14021013 1.4 0.64 INSULIN NIL CONTROLLED ACUTE GASTRITIS 104 6.8 135
49 42 F I14020538 1.4 1.02 INSULIN PRESENT UNCONTROLLED MIGRAINE 304 7.6 201
50 68 M I14020690 1.4 1.2 OHA PRESENT UNCONTROLLED VERTIGO 190 7.3 187
  
CONTROLS : 
 
S.NO AGE SEX OP/IP MAGNESIUM CREATININE TREATMENT DM RETINOPATHY CONTROLLED/ UNCON CAUSE FBS PPBS
1 48 M I14021249 1.8 0.62 NA NA NA LRTI 105 125
2 61 M I14020996 1.7 0.6 NA NA NA VIRAL FEVER 96 120
3 51 M I14020510 1.2 0.89 NA NA NA AGE 105 112
4 62 F I14021161 1.7 0.95 NA NA NA UTI 93 128
5 40 M I14021240 2 0.61 NA NA NA UTI 91 123
6 73 M I14020252 1.5 0.42 NA NA NA URTI 96 114
7 75 F I14021443 1.6 1.01 NA NA NA MYALGIA 99 125
8 49 M I1402494 2 0.84 NA NA NA GERD 102 124
9 40 F I14021638 1.6 0.53 NA NA NA APD 103 129
10 81 M I14020584 1.8 0.48 NA NA NA APD 100 112
11 52 M I14021120 1.9 0.65 NA NA NA URTI 86 91
12 40 F I14021492 1.6 0.53 NA NA NA UTI 101 115
13 56 F I14021470 1.4 0.67 NA NA NA MYALGIA 109 110
14 41 F I14021594 2 0.75 NA NA NA APD 92 115
15 63 M I14019835 1.7 1.07 NA NA NA URTI 104 116
16 41 M I14018351 1.8 0.91 NA NA NA MYALGIA 106 125
17 73 M I14016975 1.9 0.84 NA NA NA OA KNEE 104 135
18 57 M I14019532 1.3 1.08 NA NA NA VIRAL FEVER 98 124
19 40 F I14019924 1.6 0.66 NA NA NA LRTI 102 114
20 80 M I14020067 1.5 0.55 NA NA NA MYALGIA 110 138
21 58 M O02025990 1.8 1.1 NA NA NA MYALGIA 108 128
22 43 M I14019826 1.9 0.91 NA NA NA GERD 102 125
23 60 M I14019699 1.6 1.02 NA NA NA UTI 104 130
24 48 F I14023338 1.7 1.02 NA NA NA GERD 102 136
25 74 F I14023291 1.6 0.6 NA NA NA GERD 96 135
26 42 M            I14022922 1.6 0.5 NA NA NA FEVER 85 126
27 82 M I14022940 1.5 0.3 NA NA NA UTI 98 137
28 72 M I14022915 1.7 0.9 NA NA NA LRTI 102 110
29 50 M I14022936 2.1 1.2 NA NA NA MYALGIA 106 105
30 63 M I14022959 1.7 1 NA NA NA MYALGIA 103 116
31 60 M I14022939 1.9 0.8 NA NA NA LRTI 115 118
32 62 M I14022733 1.8 0.7 NA NA NA MYALGIA 114 111
33 76 M I14022874 1.8 0.9 NA NA NA SINUSITIS 119 108
34 71 F I14024570 1.3 0.8 NA NA NA LRTI 110 139
35 63 M I14024325 1.8 0.2 NA NA NA ACUTE PROSTATITIS 102 132
36 76 M I14025324 1.6 0.3 NA NA NA COPD 98 130
37 57 M I14025325 1.7 0.9 NA NA NA VIRAL FEVER 98 134
38 48 M I14025336 1.7 1.2 NA NA NA LIVER ABSCESS 104 115
39 45 M I14025338 1.5 0.6 NA NA NA DENGUE 114 132
40 65 F I14025246 1.7 1.1 NA NA NA UTI 98 110
41 50 M I14024110 1.9 1 NA NA NA MYALGIA 105 125
42 73 M I14024704 1.8 0.8 NA NA NA GERD 114 136
43 44 M I14024873 2.1 0.7 NA NA NA MALARIA 102 140
44 48 F I14025190 1.7 0.8 NA NA NA VIRAL FEVER 105 125
45 47 F I14025203 1.6 0.9 NA NA NA VIRAL FEVER 110 136
46 75 M I14023532 1.7 0.8 NA NA NA URTI 104 136
47 60 M I14025114 1.6 1.1 NA NA NA ACUTE SINUSITIS 114 125
48 38 M I14025189 1.9 0.9 NA NA NA CELLULITIS 86 140
49 48 F I14025019 2 0.7 NA NA NA UTI 94 112
50 77 M I14025125 1.7 0.5 NA NA NA VIRAL FEVER 102 136
  
 
  
 
 
